0000725394
false
2023
FY















































































































































































0000725394


2022-07-01
2023-06-30




0000725394


2022-12-31




0000725394


2023-10-13




0000725394


2021-07-01
2022-06-30




0000725394


2023-06-30




0000725394


2022-06-30




0000725394

DFCO:SeriesIPreferredStockMember



2023-06-30




0000725394

DFCO:SeriesIPreferredStockMember



2022-06-30




0000725394

us-gaap:SeriesHPreferredStockMember



2023-06-30




0000725394

us-gaap:SeriesHPreferredStockMember



2022-06-30




0000725394

us-gaap:SeriesGPreferredStockMember



2023-06-30




0000725394

us-gaap:SeriesGPreferredStockMember



2022-06-30




0000725394

us-gaap:SeriesFPreferredStockMember



2023-06-30




0000725394

us-gaap:SeriesFPreferredStockMember



2022-06-30




0000725394

DFCO:PreferredStockSeriesIMember



2021-06-30




0000725394

DFCO:PreferredStockSeriesHMember



2021-06-30




0000725394

DFCO:PreferredStockSeriesGMember



2021-06-30




0000725394

DFCO:PreferredStockSeriesFMember



2021-06-30




0000725394

us-gaap:CommonStockMember



2021-06-30




0000725394

DFCO:CommonStockToBeIssuedMember



2021-06-30




0000725394

DFCO:PreferredStocktobeIssuedMember



2021-06-30




0000725394

DFCO:PreferredStockSeriesIMember



2022-06-30




0000725394

DFCO:PreferredStockSeriesHMember



2022-06-30




0000725394

DFCO:PreferredStockSeriesGMember



2022-06-30




0000725394

DFCO:PreferredStockSeriesFMember



2022-06-30




0000725394

us-gaap:CommonStockMember



2022-06-30




0000725394

DFCO:CommonStockToBeIssuedMember



2022-06-30




0000725394

DFCO:PreferredStocktobeIssuedMember



2022-06-30




0000725394

us-gaap:AdditionalPaidInCapitalMember



2021-06-30




0000725394

us-gaap:RetainedEarningsMember



2021-06-30




0000725394

us-gaap:AccumulatedOtherComprehensiveIncomeMember



2021-06-30




0000725394

DFCO:TotalDalradaFinancialCorpsStockholdersDeficitMember



2021-06-30




0000725394

us-gaap:NoncontrollingInterestMember



2021-06-30




0000725394


2021-06-30




0000725394

us-gaap:AdditionalPaidInCapitalMember



2022-06-30




0000725394

us-gaap:RetainedEarningsMember



2022-06-30




0000725394

us-gaap:AccumulatedOtherComprehensiveIncomeMember



2022-06-30




0000725394

DFCO:TotalDalradaFinancialCorpsStockholdersDeficitMember



2022-06-30




0000725394

us-gaap:NoncontrollingInterestMember



2022-06-30




0000725394

DFCO:PreferredStockSeriesIMember



2021-07-01
2022-06-30




0000725394

DFCO:PreferredStockSeriesHMember



2021-07-01
2022-06-30




0000725394

DFCO:PreferredStockSeriesGMember



2021-07-01
2022-06-30




0000725394

DFCO:PreferredStockSeriesFMember



2021-07-01
2022-06-30




0000725394

us-gaap:CommonStockMember



2021-07-01
2022-06-30




0000725394

DFCO:CommonStockToBeIssuedMember



2021-07-01
2022-06-30




0000725394

DFCO:PreferredStocktobeIssuedMember



2021-07-01
2022-06-30




0000725394

DFCO:PreferredStockSeriesIMember



2022-07-01
2023-06-30




0000725394

DFCO:PreferredStockSeriesHMember



2022-07-01
2023-06-30




0000725394

DFCO:PreferredStockSeriesGMember



2022-07-01
2023-06-30




0000725394

DFCO:PreferredStockSeriesFMember



2022-07-01
2023-06-30




0000725394

us-gaap:CommonStockMember



2022-07-01
2023-06-30




0000725394

DFCO:CommonStockToBeIssuedMember



2022-07-01
2023-06-30




0000725394

DFCO:PreferredStocktobeIssuedMember



2022-07-01
2023-06-30




0000725394

us-gaap:AdditionalPaidInCapitalMember



2021-07-01
2022-06-30




0000725394

us-gaap:RetainedEarningsMember



2021-07-01
2022-06-30




0000725394

us-gaap:AccumulatedOtherComprehensiveIncomeMember



2021-07-01
2022-06-30




0000725394

DFCO:TotalDalradaFinancialCorpsStockholdersDeficitMember



2021-07-01
2022-06-30




0000725394

us-gaap:NoncontrollingInterestMember



2021-07-01
2022-06-30




0000725394

us-gaap:AdditionalPaidInCapitalMember



2022-07-01
2023-06-30




0000725394

us-gaap:RetainedEarningsMember



2022-07-01
2023-06-30




0000725394

us-gaap:AccumulatedOtherComprehensiveIncomeMember



2022-07-01
2023-06-30




0000725394

DFCO:TotalDalradaFinancialCorpsStockholdersDeficitMember



2022-07-01
2023-06-30




0000725394

us-gaap:NoncontrollingInterestMember



2022-07-01
2023-06-30




0000725394

DFCO:PreferredStockSeriesIMember



2023-06-30




0000725394

DFCO:PreferredStockSeriesHMember



2023-06-30




0000725394

DFCO:PreferredStockSeriesGMember



2023-06-30




0000725394

DFCO:PreferredStockSeriesFMember



2023-06-30




0000725394

us-gaap:CommonStockMember



2023-06-30




0000725394

DFCO:CommonStockToBeIssuedMember



2023-06-30




0000725394

DFCO:PreferredStocktobeIssuedMember



2023-06-30




0000725394

us-gaap:AdditionalPaidInCapitalMember



2023-06-30




0000725394

us-gaap:RetainedEarningsMember



2023-06-30




0000725394

us-gaap:AccumulatedOtherComprehensiveIncomeMember



2023-06-30




0000725394

DFCO:TotalDalradaFinancialCorpsStockholdersDeficitMember



2023-06-30




0000725394

us-gaap:NoncontrollingInterestMember



2023-06-30




0000725394

us-gaap:SalesRevenueNetMember
us-gaap:CustomerConcentrationRiskMember
DFCO:HealthcareInsurersAndGovernmentPayersMember



2022-07-01
2023-06-30




0000725394

us-gaap:SalesRevenueNetMember
us-gaap:CustomerConcentrationRiskMember
DFCO:HealthcareInsurersAndGovernmentPayersMember



2021-07-01
2022-06-30




0000725394

DFCO:HealthcareInsurersAndGovernmentPayersMember



2022-07-01
2023-06-30




0000725394

DFCO:HealthcareInsurersAndGovernmentPayersMember



2021-07-01
2022-06-30




0000725394

DFCO:HealthcareInsurersAndGovernmentPayersMember



2023-06-30




0000725394

DFCO:HealthcareInsurersAndGovernmentPayersMember



2022-06-30




0000725394

DFCO:AverettUniversaryMember



2022-07-01
2023-06-30




0000725394

us-gaap:SalesRevenueNetMember
us-gaap:CustomerConcentrationRiskMember
DFCO:AverettUniversaryMember



2022-07-01
2023-06-30




0000725394

us-gaap:SalesRevenueNetMember
us-gaap:CustomerConcentrationRiskMember
DFCO:Covid19Member



2022-07-01
2023-06-30




0000725394

us-gaap:SalesRevenueNetMember
us-gaap:CustomerConcentrationRiskMember
DFCO:Covid19Member



2021-07-01
2022-06-30




0000725394

us-gaap:FairValueInputsLevel1Member
DFCO:ContingentConsiderationMember



2023-06-30




0000725394

us-gaap:FairValueInputsLevel2Member
DFCO:ContingentConsiderationMember



2023-06-30




0000725394

us-gaap:FairValueInputsLevel3Member
DFCO:ContingentConsiderationMember



2023-06-30




0000725394

DFCO:ContingentConsiderationMember



2023-06-30




0000725394

us-gaap:FairValueInputsLevel1Member



2023-06-30




0000725394

us-gaap:FairValueInputsLevel2Member



2023-06-30




0000725394

us-gaap:FairValueInputsLevel3Member



2023-06-30




0000725394

us-gaap:FairValueInputsLevel1Member
DFCO:ContingentConsiderationMember



2022-06-30




0000725394

us-gaap:FairValueInputsLevel2Member
DFCO:ContingentConsiderationMember



2022-06-30




0000725394

us-gaap:FairValueInputsLevel3Member
DFCO:ContingentConsiderationMember



2022-06-30




0000725394

DFCO:ContingentConsiderationMember



2022-06-30




0000725394

us-gaap:FairValueInputsLevel1Member



2022-06-30




0000725394

us-gaap:FairValueInputsLevel2Member



2022-06-30




0000725394

us-gaap:FairValueInputsLevel3Member



2022-06-30




0000725394

DFCO:ComputerAndOfficeEquipmentMember



2022-07-01
2023-06-30




0000725394

us-gaap:MachineryAndEquipmentMember



2022-07-01
2023-06-30




0000725394

us-gaap:LeaseholdImprovementsMember



2022-07-01
2023-06-30




0000725394

DFCO:ProductSalesThirdPartiesMember



2022-07-01
2023-06-30




0000725394

DFCO:ProductSalesThirdPartiesMember



2021-07-01
2022-06-30




0000725394

DFCO:ProductSalesRelatedPartiesMember



2022-07-01
2023-06-30




0000725394

DFCO:ProductSalesRelatedPartiesMember



2021-07-01
2022-06-30




0000725394

DFCO:ServiceRevenueThirdPartiesMember



2022-07-01
2023-06-30




0000725394

DFCO:ServiceRevenueThirdPartiesMember



2021-07-01
2022-06-30




0000725394

DFCO:ServiceRevenueRelatedPartyMember



2022-07-01
2023-06-30




0000725394

DFCO:ServiceRevenueRelatedPartyMember



2021-07-01
2022-06-30




0000725394

DFCO:ProductSalesMember



2022-07-01
2023-06-30




0000725394

DFCO:ProductSalesMember



2021-07-01
2022-06-30




0000725394

us-gaap:ServiceMember



2022-07-01
2023-06-30




0000725394

us-gaap:ServiceMember



2021-07-01
2022-06-30




0000725394

us-gaap:ConvertibleNotesPayableMember



2022-07-01
2023-06-30




0000725394

us-gaap:ConvertibleNotesPayableMember



2021-07-01
2022-06-30




0000725394

DFCO:CommonStockWarrantsMember



2022-07-01
2023-06-30




0000725394

DFCO:CommonStockWarrantsMember



2021-07-01
2022-06-30




0000725394

DFCO:DalradaMember



2021-08-31




0000725394

DFCO:DalradaMember
DFCO:PartnershipAgreementMember



2021-08-01
2021-08-31




0000725394


2021-08-01
2021-08-31




0000725394

DFCO:DalradaMember
DFCO:JVAgreementMember



2021-10-01
2021-10-31




0000725394

DFCO:DalradaMember
DFCO:JVAgreementMember



2021-07-01
2022-06-30




0000725394

DFCO:ViveraMember



2021-12-31




0000725394


2022-10-16
2022-10-17




0000725394


2022-10-17




0000725394


2023-02-28
2023-03-01




0000725394


2023-03-01




0000725394

DFCO:DepositionTechnologyLtdMember



2022-04-06
2022-04-07




0000725394

DFCO:DepositionTechnologyLtdMember
us-gaap:CommonStockMember



2022-04-06
2022-04-07




0000725394

DFCO:WastonRxLLCMember



2022-06-06
2022-06-07




0000725394


2022-06-06
2022-06-07




0000725394

DFCO:WastonRxLLCMember
us-gaap:CommonStockMember



2022-06-06
2022-06-07




0000725394

DFCO:BothOfBrothersConstructionIncMember



2022-07-01
2023-06-30




0000725394

DFCO:DalradaTechnologyLTDEUMember



2022-07-01
2023-06-30




0000725394

DFCO:DepositionTechnologyLtdMember



2022-07-01
2023-06-30




0000725394

DFCO:WastonRxLLCMember



2022-07-01
2023-06-30




0000725394

DFCO:BothOfBrothersConstructionIncMember



2022-10-17




0000725394

DFCO:DalradaTechnologyLTDEUMember



2023-03-01




0000725394

DFCO:DepositionTechnologyLtdMember



2022-04-07




0000725394

DFCO:WastonRxLLCMember



2022-06-07




0000725394

DFCO:PrecisionMember



2022-06-30




0000725394

DFCO:HealthMember



2022-06-30




0000725394

DFCO:PrecisionMember



2022-07-01
2023-06-30




0000725394

DFCO:HealthMember



2022-07-01
2023-06-30




0000725394

DFCO:PrecisionMember



2023-06-30




0000725394

DFCO:HealthMember



2023-06-30




0000725394

DFCO:PrecisionMember



2021-06-30




0000725394

DFCO:HealthMember



2021-06-30




0000725394

DFCO:PrecisionMember



2021-07-01
2022-06-30




0000725394

DFCO:HealthMember



2021-07-01
2022-06-30




0000725394

DFCO:CurriculumDevelopmentMember



2022-06-30




0000725394

us-gaap:LicenseMember



2022-06-30




0000725394

us-gaap:CustomerRelationshipsMember



2022-06-30




0000725394

us-gaap:TrademarksMember



2022-06-30




0000725394

DFCO:DevelopedTechnologySoftwareAndOtherMember



2022-06-30




0000725394

DFCO:CurriculumDevelopmentMember



2022-07-01
2023-06-30




0000725394

us-gaap:LicenseMember



2022-07-01
2023-06-30




0000725394

us-gaap:CustomerRelationshipsMember



2022-07-01
2023-06-30




0000725394

us-gaap:TrademarksMember



2022-07-01
2023-06-30




0000725394

DFCO:DevelopedTechnologySoftwareAndOtherMember



2022-07-01
2023-06-30




0000725394

DFCO:CurriculumDevelopmentMember



2023-06-30




0000725394

us-gaap:LicenseMember



2023-06-30




0000725394

us-gaap:CustomerRelationshipsMember



2023-06-30




0000725394

us-gaap:TrademarksMember



2023-06-30




0000725394

DFCO:DevelopedTechnologySoftwareAndOtherMember



2023-06-30




0000725394

DFCO:CurriculumDevelopmentMember



2021-06-30




0000725394

us-gaap:LicenseMember



2021-06-30




0000725394

us-gaap:CustomerRelationshipsMember



2021-06-30




0000725394

us-gaap:TrademarksMember



2021-06-30




0000725394

DFCO:DevelopedTechnologySoftwareAndOtherMember



2021-06-30




0000725394

DFCO:CurriculumDevelopmentMember



2021-07-01
2022-06-30




0000725394

us-gaap:LicenseMember



2021-07-01
2022-06-30




0000725394

us-gaap:CustomerRelationshipsMember



2021-07-01
2022-06-30




0000725394

us-gaap:TrademarksMember



2021-07-01
2022-06-30




0000725394

DFCO:DevelopedTechnologySoftwareAndOtherMember



2021-07-01
2022-06-30




0000725394

DFCO:NotePayableRelatedPartyEntityOneMember



2023-06-30




0000725394

DFCO:NotePayableRelatedPartyEntityTwoMember



2023-06-30




0000725394

DFCO:NotePayableRelatedPartyEntityThreeMember



2023-06-30




0000725394

DFCO:NotePayableRelatedPartyEntityFourMember



2023-06-30




0000725394

DFCO:NotePayableRelatedPartyEntityFiveMember



2023-06-30




0000725394

DFCO:NotePayableRelatedPartyEntitySixMember



2023-06-30




0000725394

DFCO:NotePayableRelatedPartyEntityOneMember



2022-06-30




0000725394

DFCO:NotePayableRelatedPartyEntityTwoMember



2022-06-30




0000725394

DFCO:NotePayableRelatedPartyEntityThreeMember



2022-06-30




0000725394

DFCO:NotePayableRelatedPartyEntityFourMember



2022-06-30




0000725394

DFCO:NotePayableRelatedPartyEntityFiveMember



2022-06-30




0000725394

DFCO:NotesPayableRelatedPartiesMember



2022-12-31




0000725394

DFCO:NotesPayableRelatedPartiesMember



2022-12-30
2022-12-31




0000725394

DFCO:NotesPayableRelatedParties1Member



2022-12-31




0000725394

DFCO:NotesPayableRelatedPartiesMember



2023-06-30




0000725394

DFCO:NotesPayableRelatedPartiesMember



2022-06-30




0000725394

DFCO:NotesPayableRelatedPartiesMember



2023-01-01
2023-06-30




0000725394

DFCO:NotesPayableRelatedPartiesMember



2022-01-01
2022-06-30




0000725394

DFCO:WastonRxMember



2022-07-01
2023-06-30




0000725394

DFCO:COVID19GovernmentLoanMember



2022-07-01
2023-06-30




0000725394

DFCO:COVID19GovernmentLoanMember



2021-07-01
2022-06-30




0000725394

DFCO:WatsonMember



2023-06-30




0000725394

DFCO:WatsonMember



2022-06-30




0000725394

DFCO:WatsonMember



2022-07-01
2023-06-30




0000725394

DFCO:WatsonMember



2023-06-26




0000725394

DFCO:SecuritiesPurchaseAgreementMember
DFCO:YaIIPNDebenturesMember



2022-02-04




0000725394

DFCO:SecuritiesPurchaseAgreementMember
DFCO:YaIIPNDebenturesMember



2022-02-02
2022-03-31




0000725394

DFCO:SecuritiesPurchaseAgreementMember
DFCO:YaIIPNDebenturesMember



2022-02-03
2022-02-04




0000725394

us-gaap:ConvertibleDebtMember



2022-07-01
2023-06-30




0000725394

DFCO:SecuritiesPurchaseAgreementMember
DFCO:YaIIPNDebenturesMember



2022-07-01
2023-06-30




0000725394

DFCO:SecuritiesPurchaseAgreementMember
DFCO:YaIIPNDebenturesMember



2021-07-01
2022-06-30




0000725394

DFCO:SecuritiesPurchaseAgreementMember
DFCO:YaIIPNDebenturesMember



2023-06-30




0000725394

DFCO:SecuritiesPurchaseAgreementMember
DFCO:YaIIPNDebenturesMember



2022-06-30




0000725394

DFCO:NotePayableMember



2023-06-30




0000725394

DFCO:ConvertibleNoteMember



2023-06-30




0000725394

DFCO:ConvertibleNoteMember



2022-07-01
2023-06-30




0000725394

DFCO:PrincipalMember
DFCO:SeriesGConvertiblePreferredStockMember



2022-02-01




0000725394

DFCO:SeriesGConvertiblePreferredStockMember



2022-01-30
2022-02-01




0000725394

DFCO:SeriesGConvertibleCommonStockMember



2022-01-30
2022-02-01




0000725394

DFCO:SeriesGConvertibleCommonStockMember



2022-02-01




0000725394

DFCO:PrincipalMember
DFCO:SeriesHConvertiblePreferredStockMember



2023-04-04




0000725394

DFCO:SeriesHConvertiblePreferredStockMember



2023-04-03
2023-04-04




0000725394

DFCO:SeriesHConvertibleCommonStockMember



2023-04-03
2023-04-04




0000725394

DFCO:SeriesHConvertibleCommonStockMember



2023-04-04




0000725394

DFCO:PrincipalMember
DFCO:SeriesIConvertiblePreferredStockMember



2023-06-23




0000725394

DFCO:SeriesIConvertiblePreferredStockMember



2023-06-22
2023-06-23




0000725394

DFCO:SeriesIConvertibleCommonStockMember



2023-06-22
2023-06-23




0000725394

DFCO:SeriesIConvertibleCommonStockMember



2023-06-23




0000725394

DFCO:CashFromRelatedPartiesMember



2022-07-01
2023-06-30




0000725394

us-gaap:RelatedPartyMember



2022-07-01
2023-06-30




0000725394

DFCO:BothofBrothersMember
DFCO:ConstructionServicesMember



2022-07-01
2023-06-30




0000725394

DFCO:DalradaEnergyServicesMember
DFCO:InterestIncomeAndRoyaltyRevenueMember



2022-07-01
2023-06-30




0000725394

DFCO:NonEmployeeBoardMember



2022-07-01
2023-06-30




0000725394

DFCO:CashFromRelatedPartiesMember



2023-06-30




0000725394

DFCO:CashFromRelatedPartiesMember



2021-07-01
2022-06-30




0000725394

DFCO:CashFromRelatedPartiesMember



2022-06-30




0000725394

DFCO:ServicesProvidedByRelatedPartiesMember



2021-07-01
2022-06-30




0000725394

DFCO:ServicesProvidedByRelatedPartiesMember



2022-06-30




0000725394

DFCO:ServicesPerformedByNonEmployeeBoardMembersMember



2021-07-01
2022-06-30




0000725394

DFCO:ServicesPerformedByNonEmployeeBoardMembersMember



2022-06-30




0000725394

DFCO:CovidTestingMember



2021-07-01
2022-06-30




0000725394

DFCO:DalradaHealthMember



2022-07-01
2023-06-30




0000725394

DFCO:DalradaHealthMember



2021-07-01
2022-06-30




0000725394

DFCO:DalradaEnergyServicesMember



2022-07-01
2023-06-30




0000725394

DFCO:DalradaEnergyServicesMember



2021-07-01
2022-06-30




0000725394

DFCO:SolasMember



2022-07-01
2023-06-30




0000725394

DFCO:SolasMember



2021-07-01
2022-06-30




0000725394

DFCO:DalradaEnergyServicesOneMember



2022-07-01
2023-06-30




0000725394

DFCO:DalradaEnergyServicesOneMember



2021-07-01
2022-06-30




0000725394

DFCO:IgniteMember



2022-07-01
2023-06-30




0000725394

DFCO:IgniteMember



2021-07-01
2022-06-30




0000725394

DFCO:PrakatMember



2022-07-01
2023-06-30




0000725394

DFCO:PrakatMember



2021-07-01
2022-06-30




0000725394

DFCO:BothofBrothersMember



2022-07-01
2023-06-30




0000725394

DFCO:BothofBrothersMember



2021-07-01
2022-06-30




0000725394

DFCO:DepositionTechnologyLtdMember



2023-03-02
2023-03-31




0000725394

DFCO:DepositionTechnologyLtdMember



2022-12-01
2022-12-31




0000725394

DFCO:DepositionTechnologyLtdMember



2022-11-01
2022-11-30




0000725394

DFCO:DepositionTechnologyLtdMember



2022-07-01
2022-07-31




0000725394

DFCO:DepositionTechnologyLtdMember



2023-06-01
2023-06-30




0000725394

DFCO:ConsultantMember



2022-07-01
2022-07-31




0000725394

DFCO:WatsonMember



2023-03-02
2023-03-31




0000725394

DFCO:WatsonMember



2022-12-01
2022-12-31




0000725394

DFCO:WatsonMember



2023-04-01
2023-04-30




0000725394

DFCO:InternationalHealthGroupMember



2022-09-01
2022-09-30




0000725394

DFCO:InternationalHealthGroupMember



2022-12-01
2022-12-31




0000725394

DFCO:InternationalHealthGroupMember



2023-03-02
2023-03-31




0000725394

DFCO:PacificStemCellsMember
us-gaap:CommonStockMember



2022-12-01
2022-12-31




0000725394

DFCO:PacificStemCellsMember
us-gaap:CommonStockMember



2022-09-01
2022-09-30




0000725394

us-gaap:CommonStockMember
us-gaap:ConvertibleDebtMember



2022-07-01
2023-06-30




0000725394

DFCO:ConsultantMember



2023-04-01
2023-04-30




0000725394

DFCO:PacificStemCellsMember
us-gaap:CommonStockMember



2021-08-01
2021-08-31




0000725394

DFCO:PacificStemCellsMember
us-gaap:CommonStockMember



2021-12-01
2021-12-31




0000725394

DFCO:PacificStemCellsMember
us-gaap:CommonStockMember



2022-03-01
2022-03-31




0000725394

DFCO:PacificStemCellsMember
us-gaap:CommonStockMember



2022-05-01
2022-05-31




0000725394

DFCO:InternationalHealthGroupMember



2021-10-01
2021-10-31




0000725394

DFCO:InternationalHealthGroupMember



2021-12-01
2021-12-31




0000725394

DFCO:InternationalHealthGroupMember



2022-03-01
2022-03-31




0000725394

DFCO:InternationalHealthGroupMember



2022-05-01
2022-05-31




0000725394

us-gaap:CommonStockMember
DFCO:EmployeeMember



2021-09-01
2021-09-30




0000725394

us-gaap:CommonStockMember
DFCO:EmployeeMember



2021-09-30




0000725394

DFCO:BoardOfDirectorsMember



2021-09-01
2021-09-30




0000725394

DFCO:BoardOfDirectorsMember



2021-07-18
2021-07-19




0000725394

DFCO:BoardOfDirectorsMember



2021-07-19




0000725394

DFCO:PalaAgreementMember



2021-10-01
2021-10-31




0000725394

DFCO:ConsultantMember



2021-12-01
2021-12-31




0000725394

DFCO:ConsultantMember



2021-12-19
2021-12-20




0000725394

DFCO:HealthcareManagementServicesMember



2021-12-20




0000725394

srt:BoardOfDirectorsChairmanMember



2021-12-01
2021-12-31




0000725394

DFCO:ConsultantMember



2022-03-01
2022-03-31




0000725394

us-gaap:CommonStockMember



2022-06-01
2022-06-30




0000725394

DFCO:CommonStock1Member



2022-06-01
2022-06-30




0000725394

DFCO:WatsonMember



2022-06-01
2022-06-30




0000725394

DFCO:Dalrada2020StockCompPlanMember
DFCO:BoardMembersMember



2020-07-08
2020-07-09




0000725394

DFCO:Dalrada2020StockCompPlanMember



2021-02-25




0000725394

srt:BoardOfDirectorsChairmanMember



2021-11-02
2021-11-10




0000725394

srt:BoardOfDirectorsChairmanMember



2021-11-10




0000725394

DFCO:EmployeeMember



2021-11-28
2021-11-30




0000725394

DFCO:EmployeeMember



2021-11-30




0000725394

us-gaap:CommonStockMember



2022-02-12
2022-02-16




0000725394


2022-02-16




0000725394


2022-02-12
2022-02-16




0000725394

DFCO:BoardOfDirectorsAndAdvisorsMember



2022-08-10
2022-08-11




0000725394

DFCO:BoardOfDirectorsAndAdvisorsMember



2022-08-11




0000725394


2022-08-11




0000725394

us-gaap:CommonStockMember
DFCO:BothofBrothersMember



2022-10-06
2022-10-07




0000725394

DFCO:BothofBrothersMember
us-gaap:CommonStockMember



2022-10-07




0000725394

DFCO:BothofBrothersMember



2022-10-06
2022-10-07




0000725394

DFCO:DalradaTechnologyLtdMember



2023-02-27
2023-03-01




0000725394

DFCO:DalradaTechnologyLtdMember



2023-03-01




0000725394

srt:OfficerMember



2023-04-10
2023-04-14




0000725394

us-gaap:WarrantMember



2023-04-14




0000725394

DFCO:Warrant1Member



2023-04-14




0000725394

DFCO:Warrant2Member



2023-04-14




0000725394

DFCO:Warrant3Member



2023-04-14




0000725394

DFCO:Warrant4Member



2023-04-14




0000725394

DFCO:Warrant5Member



2023-04-14




0000725394

DFCO:Warrant6Member



2023-04-14




0000725394

DFCO:Warrant7Member



2023-04-14




0000725394

DFCO:Warrant8Member



2023-04-14




0000725394

DFCO:Warrant9Member



2023-04-14




0000725394

DFCO:Warrant10Member



2023-04-14




0000725394


2023-04-10
2023-04-14




0000725394

DFCO:EmployeesMember



2023-05-15
2023-05-25




0000725394

us-gaap:WarrantMember



2023-05-25




0000725394

DFCO:Warrant1Member



2023-05-25




0000725394


2023-05-15
2023-05-25




0000725394


2020-07-01
2021-06-30




0000725394

DFCO:StockCompensationPlan2020Member



2022-07-01
2023-06-30




0000725394

DFCO:StockCompensationPlan2020Member



2021-07-01
2022-06-30




0000725394

DFCO:GeneficMember



2022-07-01
2023-06-30




0000725394

DFCO:DalradaEnergyMember



2022-07-01
2023-06-30




0000725394

DFCO:DalradaPrecisionManufacturingMember



2022-07-01
2023-06-30




0000725394

DFCO:DalradaTechnologiesMember



2022-07-01
2023-06-30




0000725394

us-gaap:CorporateMember



2022-07-01
2023-06-30




0000725394

DFCO:GeneficMember



2021-07-01
2022-06-30




0000725394

DFCO:DalradaEnergyMember



2021-07-01
2022-06-30




0000725394

DFCO:DalradaPrecisionManufacturingMember



2021-07-01
2022-06-30




0000725394

DFCO:DalradaTechnologiesMember



2021-07-01
2022-06-30




0000725394

us-gaap:CorporateMember



2021-07-01
2022-06-30




0000725394

country:US



2022-07-01
2023-06-30




0000725394

country:US



2021-07-01
2022-06-30




0000725394

country:GB



2022-07-01
2023-06-30




0000725394

country:GB



2021-07-01
2022-06-30




0000725394

country:IN



2022-07-01
2023-06-30




0000725394

country:IN



2021-07-01
2022-06-30




0000725394

country:US



2023-06-30




0000725394

country:US



2022-06-30




0000725394

country:GB



2023-06-30




0000725394

country:GB



2022-06-30




0000725394

country:IN



2023-06-30




0000725394

country:IN



2022-06-30




0000725394

DFCO:EscondidoCaMember



2022-07-31




0000725394

DFCO:PrakatSubsidiaryMember



2023-04-30




0000725394

DFCO:PowayCaMember



2021-05-31




0000725394

DFCO:ChulaVistaCAMember



2022-01-31




0000725394

DFCO:SanDiegoCAMember



2022-05-31




0000725394

DFCO:DepTecSubsidiaryMember



2020-08-31




0000725394

DFCO:FlorenceAlabamaMember



2021-05-31




0000725394

DFCO:EscondidoCaMember
DFCO:EmpowerSubsidiaryMember



2022-07-31




0000725394

DFCO:SanDiegoCaliforniaMember



2022-10-31




0000725394

DFCO:EscondidoCaMember



2022-10-31




0000725394

DFCO:CoronadoCaliforniaMember



2023-01-31




0000725394

DFCO:GlasgowScotlandMember



2023-03-31




0000725394

DFCO:SanDiegoCaliforniaMember



2023-03-31




0000725394

DFCO:BergondoSpainMember



2023-03-31



iso4217:USD


xbrli:shares




iso4217:USD


xbrli:shares




xbrli:pure


Table of Contents

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-K

 

ANNUAL REPORT UNDER SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the fiscal year ended June 30, 2023

 

 TRANSITION REPORT UNDER SECTION 13
OR 15 (d) OF THE EXCHANGE ACT

 

For the transition period from _________ to _________

 

Commission File Number: 000-12641

 

DALRADA FINANCIAL CORPORATION

(Name of Small Business Issuer in its charter)

 

Wyoming 38-3713274
(state or other jurisdiction of incorporation or organization) (I.R.S. Employer ID. No.)

 

600 La Terraza Blvd., Escondido, California 92025

(Address of principal executive offices)

 

858283-1253

Issuer’s telephone number

 

Securities registered pursuant to Section 12(b)
of the Act: None

 

Securities registered pursuant to Section 12(g)
of the Act: None

 

Title of each class   Trading Symbol   Name of each exchange on which registered
Common Stock, $0.005 par value per share   DFCO   None

  

Indicate by check mark if the registrant is a
well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☐   No

 

Indicate by check mark if the registrant is not
required to file reports pursuant to Section 13 or Section 15(d) of the Act.  Yes ☐     No

 

Indicate by check mark whether the registrant
(1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months
(or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements
for the past 90 days. Yes ☐     No

 

Indicate by check mark whether the registrant
has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405
of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).   Yes  ☐    
No

 

Indicate by check mark whether the registrant
is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company.
See the definitions of “large accelerated filer”, “accelerated filer” “smaller reporting company,”
and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer ☐   Accelerated filer ☐
Non-accelerated filer Smaller reporting company
Emerging growth company  

 

If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Indicate by check mark whether the registrant
has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial
reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or
issued its audit report. Yes No ☒

 

If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant
included in the filing reflect the correction of an error to previously issued financial statements. Indicate by check mark whether the
registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes ☐ No

 

Indicate by check mark whether any of those
error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant’s
executive officers during the relevant recovery period pursuant to §240.10D-1(b). ☐

 

Indicate by check mark whether the registrant
is a shell company (as defined in Rule 12b-2 of the Act) Yes
   No ☒

 

State the aggregate market value of the voting
and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the
average bid and asked price of such common equity, as of the last business day of the registrant’s most recently completed second
fiscal quarter: $6,009,387.

 

As of October 13, 2023, the registrant’s outstanding stock consisted
of 89,933,776 common shares.

 

 

     

 

 

DALRADA FINANCIAL CORPORATION.

 

Table of Contents

 

PART I  
     
Item 1. Description of Business 1
Item 1A. Risk Factors 4
Item 1B. Unresolved Staff Comments 4
Item 2. Description of Property 4
Item 3. Legal Proceedings 5
Item 4. Mine Safety Disclosures 5
     
PART II  
     
Item 5. Market for Common Equity, Related Stockholder Matters and Small Business Issuer Purchases of Equity Securities 6
Item 6. Selected Financial Data 8
Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operation 8
Item 7A. Quantitative and Qualitative Disclosures About Market Risk 20
Item 8. Financial Statements and Supplementary Data 21
Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure 22
Item 9A. Controls and Procedures 22
Item 9B. Other Information 22
     
PART III  
     
Item 10. Directors, Executive Officers and Corporate Governance 24
Item 11. Executive Compensation 28
Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 31
Item 13. Certain Relationships, Related Transactions and Director Independence 31
Item 14. Principal Accountant Fees and Services 33
Item 15. Exhibits and Financial Statement Schedules 34
  Signatures 35

 

 

 

 

 

 

 

  i  

 

 

PART I

 

Item 1. Description of Business

 

Company Overview

 

Moving the world forward
takes bold resolve that turns ideas into actions and builds real-time solutions that positively impact people and the planet. Dalrada
accelerates positive change for current and future generations by harnessing true potential and developing products and services that
become transformative innovations.

 

Dalrada Financial Corporation, (“Dalrada”),
was incorporated in September 1982 under the laws of the State of California. It was reincorporated in May 1983 under the laws of the
State of Delaware and reincorporated again on May 5, 2020, under the laws of the state of Wyoming. Dalrada Financial Corporation trades
under the symbol, OTCQB: DFCO.

 

Dalrada has five business divisions: Genefic
(formerly Dalrada Health)
, Dalrada Energy Services, Dalrada Precision Manufacturing, Dalrada Technologies and Dalrada
Corporate
. Within each of these divisions, the Company drives transformative innovation while creating solutions that are
sustainable, accessible, and affordable. Dalrada’s global solutions directly address climate change, gaps in the health care
industry, and technology needs that facilitate a new era of human behavior and interaction and ensure a bright future for the world
around us.

 

Genefic (formerly
Dalrada Health)

 

Genefic delivers advanced
health care solutions with dedicated products, services, and systems. From virus and disease screening capabilities to pharmaceutical
goods and holistic wellness clinics, When the world needs advanced health care, Genefic delivers with ingenuity, accessibility, and affordability.
This specialized division is committed to developing key health products, lifesaving medications and building comprehensive systems to
increase capability, strive to keep people healthy with the goals of improving their quality of life and increasing their longevity–
on a global level.

 

Empower
Genomics (“Empower”)
– Empower is Dalrada’s wholly owned diagnostic laboratory subsidiary which processes molecular
diagnostic and antibody tests to support the diagnosis of COVID-19 and the detection of immune response to the virus. Empower has built
up and maintained the testing capacity to handle surges in COVID-19 testing demands. Empower also offers genetic testing capabilities
including Pharmacogenomics, Nutraceutical, Nutrition/Diet DNA and Exercise/Fitness DNA tests.

 

Pala
Diagnostics (“Pala”)
– Pala is a joint venture diagnostic laboratory entity which processes both molecular diagnostic and
antibody tests to support the diagnosis of COVID-19 and the detection of immune response to the virus.

 

Solas
Corp. (“Solas”)
– Solas manages and oversees wellness clinics throughout Southern California including the Sòlas
Rejuvenation + Wellness clinics (“Sòlas”). Through advanced medical techniques and modern technology, Sòlas
delivers a clinical experience that helps men and woman live their best life, whether it’s through simple cosmetic procedures, pain-reducing
practices, or anti-aging therapies. Through its three locations, Sòlas prides itself on its dedicated service-focused, health-first
approach. Its wellness & rejuvenation clinics deliver with a focus on regenerative therapies, IV and injection services, cosmetic
enhancements amongst a myriad of additional health centric services.

 

 

 

 

  1  

 

 

International
Health Group (“IHG”)
– IHG provides highly trained nursing and medical assistants for hospitals and home health facilities
since 2006. IHG Medical Assistant programs include Certified Nursing Assistant (“CNA") and Home Health Aide (“HHA”)
training and the fast-track 22-Day CNA Certification Program at its state-approved testing facility.

 

Pacific
Stem Cells (“PSC”)
– PSC markets and sells traditional biologics and human cells, tissues, and cellular and tissue-based
products (HCT/Ps).

 

Watson
Rx Solutions (“Watson”)
– In June 2022, the Company acquired Watson, an Alabama-based pharmacy with more than 30 years
of experience in the retail medical and pharmaceutical industries. Watson specializes in providing expert care and managing disease states
through comprehensive prescription management, education, nursing, and total health solutions. Watson maintains pharmacy licenses in all
50 States including Washington D.C.

 

GlanHealth
(“GlanHealth”)
– Genefic Products launched GlanHealth in 2020 to distribute alcohol-free hand sanitizers, surface cleaners,
laundry aides, antimicrobial solutions, electrostatic sprayers, face masks, gloves, kits, and delivery equipment such as dispensers, stands,
and ease of use packaging for the end consumer. GlanHealth leverages an extensive supply chain of producers, resellers, distributors,
vendors, and formulators for the development, sale, and marketing of its products and services.

 

Dalrada Energy
Services

 

Dalrada Energy Services
(‘DES’) employs next-generation technology that enhances clean energy efforts while reducing the world’s carbon footprint.
Through innovative products and commercial services, DES facilitates energy transition for universities, businesses, government buildings,
and more. Reducing the world’s carbon footprint and achieving international Net Zero goals are no easy task. Fortunately, Dalrada
Energy Services knows how and where to start. By providing robust commercial services that help organizations meet or exceed environmental
standards, DES helps mitigate negative impacts for real-world energy transition while removing cost barriers for clients through innovative
financing and savings share models.

 

Dalrada
Energy Services (“DES”)
– DES provides end-to-end comprehensive energy service solutions in a robust commercial capacity.
DES helps organizations meet environmental, social, and governance (“ESG”) goals and standards while mitigating negative environmental
impacts.

 

Bothof
Brothers Construction (“Bothof”)
– Bothof is a licensed general contractor which provides a wide range of development,
construction and design capabilities and expertise throughout the United States. Through Bothof’s extensive experience in construction
and contracting, the DES division can provide a myriad of additional services to its private and public works customers.

 

Dalrada Precision
Manufacturing

 

Dalrada Precision Manufacturing
creates total manufacturing solutions that start with the design and development of high-quality machine parts and components, and end
with an efficient global supply chain. This specialized business division can meet today’s high demands and solves industry challenges.
Dalrada Precision Manufacturing is confident that it redefines the critical quality of the world’s top components and responds with
in-house research, design, engineering, and distribution through a highly reliable global supply chain and improved time-to-market capabilities.

 

Dalrada
Precision Parts (“Precision”)
– Precision extends the client its engineering and operations team by helping devise unique
manufacturing solutions tailored to their products. Dalrada Precision can enter at any stage of the product lifecycle from concept and
design to mass production and logistics.

 

 

 

 

  2  

 

 

Likido
Ltd. (“Likido”)
– Likido is an international engineering company developing advanced solutions for the harvesting and recycling
of energy. Using its novel, heat pump systems (patent pending), Likido is working to revolutionize the renewable energy sector with the
provision of innovative modular process technologies to maximize the capture and reuse of thermal energy for integrated heating and cooling
applications. With uses across industrial, commercial and residential sectors, Likido provides cost savings and minimized carbon emissions
across global supply chains. Likido’s technologies enable the effective recovery and recycling of process energy, mitigating against climate
change and expected enhancement of quality of life through the provision of low-carbon heating and cooling systems. 

 

During
the prior year, the U.S. Government selected Dalrada’s Likido®ONE high-performance, low-carbon heat pump for real-world testing
in a prestigious clean energy program. The implementation of the Likido®ONE testing is still in process. The expected positive results
should not only increase market acceleration and adoption within the federal government acceptance of groundbreaking eco-friendly technology
but should also accelerate adoption within the commercial building industry.

 

Ignite
I.T. (“Ignite”)
– Ignite is a manufacturer and seller of eco-friendly deep cleaners, parts washers and degreasers that
are specially formulated to lift hydrocarbon-based dirt and grease from virtually all surfaces with minimal effort. Ignite products are
non-flammable, non-corrosive, non-toxic, butyl-free, water-based, and leave a light citrus scent. Ignite is developed for all surfaces
suitable for water and meets or exceed the most stringent industry-testing specifications.

 

Deposition
Technologies (“DepTec”)
– Dalrada Precision Manufacturing acquired DepTec in April 2022. DepTec designs, develops, manufactures,
and services chemical vapor and physical vapor deposition systems for the microchip and semiconductor industries.

 

DepTec
has built an impressive catalogue of precision OEM parts for PVD (Physical vapor deposition)
systems and the Company’s refurbished systems which allows clients the option of purchasing the same model of system they’ve
been using for decades –but with significant upgrades and improved efficiencies. Older systems can now operate more reliably with
additional control and monitoring plus longer lifespans. DepTec also has its own PVD and CVD (Chemical Vapor Deposition) systems, EVOS-PVD
and EVOS -CVD, which deposits metals and non-metals for microchips used in almost every standard and specialized microdevices made today
and in the future. These systems can produce a superior film layer utilized in rugged high-stress environment designs.

 

Dalrada
Technology Limited (“DTL”)-
Dalrada Precision Manufacturing Inc. entered into an Ownership Purchase Agreement to purchase
all of the membership interests in Dalrada Technology Limited on March 1, 2023. DTL is a holding company for all European based Dalrada
Precision entities.

 

Dalrada
Technology Spain L.T. (“DTS”)-
DTS was established as a Spanish subsidiary of DTL for the expansion of the manufacturing
and sale of the Company’s heat pump technology throughout Europe.

 

Dalrada Technologies

 

Dalrada Technologies has worked with some of the
world’s most recognizable companies, providing digital engineering for cutting-edge software systems and offering a host of robust
digital services. This business division connects the world with integrated technology and innovative solutions, delivering advanced capabilities
and error-free results. Dalrada Technologies creates digital products with expert computer information technology and software engineering
services for a variety of technical industries and clients in both B2B and B2C environments.

 

Prakat (“Prakat”)
Prakat is an ISO 9001-certified company that provides end-to-end technology services across various industries, improving the value chain.
The Company specializes in test engineering, accessibility engineering, product engineering, application modernization, billing and revenue
management, CRM, and block chain. Prakat provides global customers with software and technology solutions specializing in Test Engineering,
Accessibility Engineering, Product Engineering and Application Modernization.

 

 

 

  3  

 

 

Dalrada Corporate

 

Dalrada Corporate covers the activities which
support the entire suite of Dalrada subsidiaries. Dalrada Corporate includes the areas of administration, finance, human resources, legal
advice, information technology, and marketing. It also contains executive management and shareholder-related services.

 

Research and Development

 

We spent $120,000 and $656,997 on research and
development activities during the years ended June 30, 2023, and 2022, respectively. We anticipate that we will incur additional expenses
on research and development over the next 12 months. Our planned expenditures on our operations or a business combination are summarized
under the section of this annual report entitled “Management’s Discussion and Analysis of Financial Position and Results of
Operations”.

 

Item 1A. Risk Factors

 

Not applicable to smaller reporting companies.

 

Item 1B. Unresolved Staff Comments

 

Not applicable to smaller reporting companies.

 

Item 2. Description of Property

 

We currently lease 114,542 square feet of office,
medical, pharmacy and warehouse space in California, Alabama, Texas, Scotland, and India, with leases that expire through 2028.

 

The following table sets forth information with
respect to our facilities:

 

        Square        
        Footage     Lease  
Location   Type   (approximate)     Expiration  
Escondido, California   Corporate Headquarters     49,530       6/30/2027  
San Diego, California   Office     8,228       3/14/2028  
Escondido, California   Office     2,992       6/30/2027  
Chula Vista, California   Office, Medical Suite     3,200       11/12/2024  
San Diego, California   Office, Medical Suite     9,016       8/31/2028  
Poway, California   Medical Suite     2,504       7/31/2024  
Bengaluru, India   Office     3,300       4/1/2026  
Coronado,California   Office, Medical Suite     462       12/31/2024  
Florence, Alabama   Pharmacy     1,443       5/31/2024  
Livingston, Scotland   Office, Warehouse     4,500       8/27/2025  
Escondido, California   Office     167       12/31/2024  
Livingston, Scotland   Office, Warehouse     19,000       11/2/2027  
San Diego, California   R&D Laboratory Space     1,200       10/31/2023  
Bergondo, Spain   Office, Warehourse     9,000       5/31/2028  

 

 

 

  4  

 

 

Item 3. Legal Proceedings

 

Genefic Products (“Dalrada Health”),
a subsidiary of Dalrada Financial Corporation, formed a joint venture with Vivera Pharmaceuticals, Inc. (“Vivera”), whereby
Vivera is the minority member. As the managing member of the joint venture, Genefic Products, in December 2021, filed suit against Vivera
and Paul Edalat, Vivera’s Chairman and CEO, for misappropriation of funds on behalf of the joint venture in the amount of $2,104,509.
In addition to filing a cross-complaint against Genefic Products, Vivera filed a separate complaint against Dalrada Financial Corporation,
Empower Genomics (a subsidiary of Dalrada Financial Corporation), Dalrada Financial Corporation’s officers, and other unrelated
parties. The proceedings are being held at the Superior Court of the State of California, for the County of Orange – Central Justice
Center.

 

On January 10, 2023, the Company settled a dispute
between Likido Ltd. and a US based customer, MAPtech Packaging Inc (“MAPtech”). Pursuant to the settlement, the Company shall
pay the sum of $429,987 in damages, $42,374 in legal costs, and £19,754 as reimbursement for arbitration fees and expenses paid
on account by MAPtech. The Company shall pay interest at a rate of 8% per annum simple on all sums due pursuant to settlement, beginning
30 days from the date of the award.

 

Item 4. Mine Safety Disclosures

 

Not applicable to our Company.

 

 

 

 

 

 

 

 

 

 

 

 

 

  5  

 

 

PART II

 

Item 5. Market for Common Equity, Related Stockholder Matters and
Small Business Issuer Purchases of Equity Securities

 

Market Information

 

Our shares of common stock are listed on the OTC
Markets Pink Sheets under the symbol DFCO. Set forth below are high and low bid prices for our common stock for each quarterly period
in the two most recent fiscal years. Such quotations reflect inter-dealer prices, without retail mark-up, markdown or commissions and
may not necessarily represent actual transactions in the common stock.

 

Period   High     Low  
Fiscal 2023                
First Quarter ended September 30, 2022   $ 0.3700     $ 0.0900  
Second Quarter ended December 31, 2022   $ 0.1700     $ 0.0700  
Third Quarter ended March 31, 2023   $ 0.0200     $ 0.0800  
Fourth Quarter ended June 30, 2023   $ 0.1900     $ 0.0600  
                 
Fiscal 2022                
First Quarter ended September 30, 2021   $ 0.3590     $ 0.0100  
Second Quarter ended December 31, 2021   $ 0.9200     $ 0.2890  
Third Quarter ended March 31, 2022   $ 0.9190     $ 0.2650  
Fourth Quarter ended June 30, 2022   $ 0.7200     $ 0.0300  

 

Number of Holders

 

As of June 30, 2023, there were 88,699,139 issued
and outstanding shares of common stock held by a total of 560 shareholders of record.

 

Dividends

 

No cash dividends were paid on our shares of common
stock during the fiscal years ended June 30, 2023, and 2022. We have not paid any cash dividends since our inception and do not foresee
declaring any dividends on our common stock in the foreseeable future.

 

Recent Sales of Unregistered Securities

 

Common Stock Transactions – Fiscal 2023

 

In July 2022, November 2022, December 2022, March
2023 and April 2023, the Company issued a total of 1,999,998 shares of common stock related to the acquisition of DepTec (SSCe).

 

In July 2022, the Company issued 500,000 common
stock shares pursuant to a consulting agreement for management services.

 

In December 2022, March 2023 and April 2023, the
Company issued a total of 500,000 shares of common stock related to the acquisition of Watson.

 

 

 

  6  

 

 

In September 2022, December 2022, and March 2023,
the Company issued a total of 375,000 shares of common stock related to the acquisition of International Health Group. 

 

In September and December 2022, the Company issued
a total of 175,000 shares of common stock related to the acquisition of Pacific Stem Cells. 

 

During the year ended June 30, 2023, the Company issued a total of
10,974,521 shares of common stock pursuant to the conversion of $1,495,528 of convertible debt and its related premium and interest expense.

 

In April 2023, the Company issued 2,000,000 common
stock shares pursuant to a consulting agreement for management services to increase the investment community’s awareness of the Company.

 

Common Stock Transactions – Fiscal 2022

 

In August 2021, December 2021, March 2022, and
May 2022, the Company issued 87,500 shares of common stock related to the acquisition of PSC (see “Note 4. Business Combinations
and Asset Acquisition for additional information”).

 

In October 2021, December 2021, March 2022, and
May 2022, the Company issued 125,000 shares of common stock related to the acquisition IHG (see “Note 4. Business Combinations and
Asset Acquisition for additional information”).

 

In September 2021, the Company repurchased 329,478
shares of common stock from a Company employee.

 

In September 2021, the Company issued 2,000,000
shares of common stock to board members.

  

In October 2021, the Company issued 250,000 shares
to Vivera pursuant to the Pala agreement (see “Note 3. Investment in Pala Diagnostics for additional information”).

 

In December 2021, the Company issued 500,000 shares
of common stock pursuant to a consulting agreement.

 

In December 2021, the Company cancelled 6,500,000
common shares issued to its Directors, and an advisor, and returned them to treasury.

 

In March 2022, the Company issued 192,000 shares
of common stock pursuant to a consulting agreement.

 

In June of 2022, the Company issued 164,659 shares
of common stock pursuant to the conversion of $68,630 of convertible debt and its related premium and interest expense.

 

In June 2022, the Company issued 208,777 shares
of common stock pursuant to the conversion of $65,034 of convertible debt and its related premium and interest expense.

 

In June 2022, the Company issued 500,000 shares
of common stock related to the acquisition of Watson (see “Note 4. Business Combinations and Asset Acquisition for additional information”).

 

 

 

 

  7  

 

 

Preferred Stock:

 

The Company has 100,000 shares authorized of Series
F Preferred Stock (“Series F Stock”), par value, $0.01, of which 5,000 shares of Series F Stock (at a fair value of $170)
were issued to the CEO in December 2019.  Each share of Series F Stock entitles the holder to the greater of (i) one hundred thousand
votes for each share of Series F Stock, or (ii) the number of votes equal to the number of all outstanding shares of Common Stock, plus
one additional vote such that the holders of Series F Stock shall always constitute most of the voting rights of the Corporation. In any
vote or action of the holders of the Series F Stock voting together as a separate class required by law, each share of issued and outstanding
Series F Stock shall entitle the holder thereof to one vote per share. The holders of Series F Stock shall vote together with the shares
of Common Stock as one class.

 

On February 1, 2022, the Company converted $6,532,206
of related party debt principal and interest into 10,002 shares of Series G Convertible Preferred Stock (“Series G Stock”). 
The Series G Stock shall convert at one share of Series G Stock to 2,177 shares of common stock (equivalent to converting the related
dollars into common shares at $0.30 per share).  Series G Stock does not have voting rights.

 

On April 4, 2023, the Company converted $4,544,224
of related party debt principal and interest into 15,002 shares of Series H Convertible Preferred Stock (“Series H Stock”). 
The Series H Stock shall convert at one share of Series H Stock to 3,029 shares of common stock (equivalent to converting the related
dollars into common shares at $0.10 per share).  Series H Stock does not have voting rights.

 

On June 23, 2023, the Company converted $29,315,320
of related party debt principal and interest into 35,108 shares of Series I Convertible Preferred Stock (“Series I Stock”). 
The Series I Stock shall convert at one share of Series I Stock to 5,000 shares of common stock (equivalent to converting the related
dollars into common shares at $0.167 per share).  Series I Stock does not have voting rights.

 

Purchase of our Equity Securities by Officers and Directors

 

None.

 

Other Stockholder Matters

 

None

 

Item 6.  Selected Financial Data

 

Not applicable to smaller reporting companies.

  

Item 7. Management’s Discussion and Analysis of Financial Condition
and Results of Operations

 

You should read the following discussion and analysis
in conjunction with our financial statements, including the notes thereto, included in this Report. Some of the information contained
in this Report may contain forward-looking statements within the meaning of Section 27A of the Securities Exchange Act of 1933, as amended
(the “Act”) and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). This information
may involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance, or achievements
to be materially different from future results, performance or achievements expressed or implied by any forward-looking statements. Forward-looking
statements which involve assumptions and describe our future plans, strategies and expectations, are generally identifiable by the use
of the words “may,” “will,” “should,” “expect,” “anticipate,” “estimate,”
“believe,” “intend” or “project” or the negative of these words or other variations on these words
or comparable terminology. These forward-looking statements are based on assumptions that may be incorrect, and there can be no assurance
that the projections included in these forward-looking statements will come to pass. Our actual results could differ materially from those
expressed or implied by the forward-looking statements as a result of various factors. We undertake no obligation to update publicly any
forward-looking statements for any reason, even if new information becomes available or other events occur in the future.

 

 

 

 

  8  

 

 

Our Independent Registered Public Accounting Firm’s
report contains a statement that our net loss and limited working capital raise substantial doubt about our ability to continue as a going
concern. Our independent registered public accountants have stated in their report (included in Item 8 of the Financial Statements) that
our significant operating losses and working capital deficit raise substantial doubt about our ability to continue as a going concern.
We incurred a net loss of $20,627,721 and 11,571,783, respectively, for the years ended June 30, 2023 and 2022. Although the Company continues
to rely on equity and debt investors to finance its losses, it is implementing plans to achieve cost savings and other strategic objectives
to address Company profitability. In addition to raising debt and equity financing, the Company continues to focus on growing the subsidiaries
anticipated to be most profitable while reducing investments in areas that are not expected to have long-term benefits. The Company will
continue to pursue synergistic opportunities to enhance its business portfolio.

 

Acquisitions

 

During the year ended June 30, 2023, the Company
acquired a business to complement both the Dalrada Energy Services and Dalrada Precision Manufacturing segments, respectively. A total
of 4,000,000 warrants were issued in relation to the acquisitions.

 

Refer to “Note 4. Business Combinations
and Asset Acquisition” to the Consolidated Financial Statements for discussion regarding the Company’s acquisitions.

 

RESULTS OF OPERATIONS

 

The following table sets forth the results of
our operations for the years ended June 30, 2023, and 2022:

 

    Year Ended June 30, 2023  
    Genefic     Dalrada Energy     Dalrada Precision Manufacturing     Dalrada Technologies     Corporate     Consolidated  
Revenues   $ 15,740,919     $ 7,075,414     $ 4,873,225     $ 2,049,411     $     $ 29,738,969  
Income (Loss) from Operations     (5,783,441 )     (1,065,221 )     (2,461,219 )     10,634       (11,660,710 )     (20,959,957 )

 

    Year Ended June 30, 2022  
    Genefic     Dalrada Energy     Dalrada Precision Manufacturing     Dalrada Technologies     Corporate     Consolidated  
Revenues   $ 13,617,639     $ 1,261,774     $ 2,123,437     $ 2,239,763     $ 25,000     $ 19,267,613  
Income (Loss) from Operations     2,225,304       967,639       (2,834,342 )     30,177       (10,824,022 )     (10,435,244 )

 

Dalrada Financial Corporation manages five primary
segments: 1) Genefic (formerly Dalrada Health); 2) Dalrada Energy; 3) Dalrada Precision Manufacturing; 4) Dalrada Technologies; and 5)
Dalrada Corporate. The business segment data (see “Note 13 to the accompanying Consolidated Financial Statements”) should
be read in conjunction with this discussion.

 

During the year we continued to establish products
and services through a strategic vertical integration approach. Dalrada leveraged its resources to increase market share across all operating
segments as well as acquired companies to enhance and strengthen the existing suite of businesses.

 

 

 

  9  

 

 

In the first quarter of the year, our Dalrada
Energy Services subsidiary entered into an agreement with Averett University for the installation and retrofit of the various energy consuming
equipment and components across its campus.

 

In the second quarter of the year, the Company
acquired Bothof Brothers Construction, a licensed general contractor which provides a wide range of development, construction and design
capabilities and expertise throughout the United States. Through Bothof’s extensive experience in construction and contracting,
the Dalrada Energy Services division is able to provide a myriad of additional services to its private and public works customers.

 

In the third quarter, the Company acquired Dalrada
Technology Limited, to establish an existing holding company for all European subsidiaries.

 

Revenues and Cost of revenues

 

Genefic

 

Total Revenues for Genefic increased to $15,740,919,
or 15.6% from last year’s revenue of $13,617,639.

 

Pala Diagnostics (“Pala”) and Empower
Genomics (“Empower”) generated $10,338,768, or 65.7% of the total revenue for Genefic through its complexity CLIA diagnostic
laboratories, focusing primarily on Covid-19 testing services with validated PCR and Rapid antigen testing. Our diagnostic laboratories
continued to see revenue through seasonal COVID-19 surges as well as the Medicare over-the-counter (OTC) COVID-19 test demonstration program.
Furthermore, our Covid Response Field Tech teams were deployed to senior care centers, schools and universities, businesses, and community
sites throughout Southern California. During the year, Empower continued to develop its proprietary digital registration and reporting
software that meets all compliance benchmarks required by county, state, and federally funded Covid-19 programs.

 

IHG generated $1,091,934, or 6.9% of the total
revenue for Genefic. IHG’s revenue increased by $304,961 from the prior year, or 38.8%. The increase in revenue was a result of
a rising number of students entering and graduating from IHG’s Certified Nursing Assistant (“CNA”), Medical Assistant
and Home Health Aid (“HHA”) Certification programs. The cost of revenues increased by 1.6% from the prior year. The modest
increase in cost of revenue was a result of economies of scale as IHG grew its attendance and number of classes offered.

 

Solas continued to manage three primary health
and wellness clinics in San Diego through its management services agreement. The revenue generated was $1,331,612, or 8.5% of total revenue
for Genefic. The cost of revenue was $1,324,308.

 

Watson generated $2,875,326, or 18.3% of the total
revenue for Genefic. Watson’s revenue from last year was $69,160 as a result of its acquisition being completed on June 7, 2022.
During the first quarter of the year, the revenue was $95,117 and increased by $2,780,209 over the remaining three quarters. The increase
was a result of obtaining additional accreditations including the Healthcare Merchant Accreditation from the National Association of Boards
of Pharmacy (NABP) where it can be listed on the official Accredited Merchants’ list along with larger pharmacy retailers CVS, Walgreens,
and Walmart, among others. With Healthcare merchant Accreditation, Watson has proven its standards and practices to be in line with the
requirements set by large online advertising platforms such as Google and Bing. Watson also obtained the Specialty Pharmacy Accreditation
and Mail Service Pharmacy Accreditation from the Utilization Review Accreditation Commission (URAC). NABP’s Specialty Pharmacy Accreditation
signifies to patients, payers, and providers that the pharmacy organization is recognized for providing an advanced level of pharmacy
services and disease management for patients taking medications that meet special handling, storage and distribution requirements. NABP’s
Digital Pharmacy Accreditation signifies to patients, payers, and providers that the pharmacy organization is recognized for its commitment
to the highest quality health care and safe pharmacy practices over the internet. The specific Digital Pharmacy Accreditation was created
to recognize safe and legitimate pharmacies with an internet presence that stands out against the ever-growing list of rogue pharmacy
websites. These accreditations allow Watson to focus its growth as a full spectrum specialty pharmacy. The cost of revenue was $2,104,439.

 

Genefic and Shark’s sale of alcohol-free
natural sanitizers and sanitizing kits decreased by 44.5% from the prior year, from $186,166 to $103,279. The decrease was a result of
a highly competitive sanitization market and the closure of the product line. Total cost of revenue was $244,017 due to the liquidation
of the existing product inventory.

 

 

 

  10  

 

 

Dalrada Precision Manufacturing

 

Total Revenues for Dalrada Precision Manufacturing
increased to $4,873,225, or 129.5% from last year’s revenue of $2,123,437.

 

Dalrada Precision Parts generated $2,680,906,
or 55.0% of the total revenue for Dalrada Precision Manufacturing. Revenue for Dalrada Precision Parts increased by $1,333,090, or 98.9%
from the prior year. The increase in revenue was a result of increased sales with a large United States based customer and its consulting
business. The cost of revenue was $1,581,340, or 59.0% of revenue.

 

Likido Ltd.’s heat pump sales generated
$594,758, or 12.2% of the total revenue for Dalrada Precision Manufacturing. Revenue for Likido Ltd. increased by $439,540, or 283.2%
from the prior year. The increase in revenue was a result of Likido finalizing the additional R&D required for the Likido®ONE
heat pump commercialization. Furthermore, Likido built a test bed showroom in Las Vegas, Nevada to offer demonstrations for potential
customers. The cost of revenues was $94,435, or 15.9% of revenue, and includes adjustments for intercompany sales to Dalrada Energy Services.

 

DepTec generated $1,292,303, or 26.5% of the total
revenue for Dalrada Precision Manufacturing. Revenue for DepTec increased by $722,078, or 126.6% from the prior year. The increase in
revenue was a result of DepTec generating a full year of revenue. DepTec records its revenue using a cost-based input method, by which
we use actual costs incurred relative to the total estimated contract costs to determine, as a percentage, progress toward contract completion.
The cost of revenues was $1,132,831, or 87.7% of revenue.

 

Ignite’s cleaners, parts washers and degreasers
products generated $305,258, or 6.3% of total revenue for Dalrada Precision Manufacturing. Revenue for Ignite increased by $255,080, or
508.4% from the prior year. The increase in revenue was a result of Ignite generating a full year of revenue. The cost of revenue was
$388,953, or 127.4% of revenue, and includes inventory adjustments.

 

Dalrada Energy Services

 

Total Revenues for Dalrada Energy Services increased
to $7,075,414, or 460.8% from last year’s revenue of $1,261,774.

 

Dalrada Energy Services generated $4,511,533,
or 68.3% of the total revenue for the Dalrada Energy Services segment. Revenue for Dalrada Energy Services increased by $3,249,759, or
257.6% from the prior year. The increase in revenue was a result of generating energy savings reports and the design, engineering and
equipment upgrades for universities based in the United States. The cost of revenue was $2,790,145, or 61.8% of revenue, and includes
adjustments for intercompany sales from Likido (UK).

 

The Company sold the intellectual property for
Dalrada Energy Services subsequent to June 20, 2023. The Company continues to service existing contracts as of June 30, 2023, but does
not anticipate additional new contracts from this subsidiary.

 

Bothof Brothers Construction generated $2,563,881, or 36.2% of
the total revenue for the Dalrada Energy Services segment. Bothof Brothers Construction was acquired by the Company in November
2022, so did not have any revenue last fiscal year. Bothof Brothers Construction was generated through construction and contracting
services throughout the United States. Bothof Brothers’ customers include both residential and commercial projects in the
private and public sectors. During the year, $2,134,470 of revenue was generated through related
parties.

 

Dalrada Technologies

 

Total Revenue for Dalrada Technologies”
sole subsidiary, Prakat, decreased to $2,049,411, or 8.5% from the prior year’s revenue of $2,239,763. The decrease in revenue was
a result of several contracts ending their terms during the year.

 

Dalrada Corporate

 

Total Revenue for Dalrada Corporate was $25,000
in the prior year due to a legacy real estate transaction that realized income. The real estate transaction was one-off and no Corporate
revenue was generated during the year.

 

 

 

  11  

 

 

Backlog

 

Backlog represents the dollar amount of revenues
we expect to recognize in the future from agreements awarded and in progress. Backlog is not a measure defined by generally accepted accounting
principles and is not a measure of contract profitability. Our methodology for determining backlog may not be comparable to methodologies
used by other companies in determining their backlog amounts. The backlog values we disclose include anticipated revenues associated with:
(1) the original agreement amounts; (2) change orders for which we have received written confirmations from the applicable customers;
(3) change orders for which we expect to receive confirmations in the ordinary course of business; and (4) claims that we have
made against customers. We do not include expected revenues of agreements related to unconsolidated joint ventures in our backlog, except
to the extent of any contract awards we may receive from those joint ventures.

 

For amounts included in backlog that are attributable
to claims, we include unapproved claims in backlog when we have a legal basis to do so, consider collection to be probable and believe
we can reliably estimate the ultimate value. Claims revenue is included in backlog to the extent of the lesser of the amounts management
expects to recover or associated costs incurred.

 

Backlog may not be indicative of future operating
results, and agreements in our backlog may be cancelled, modified or otherwise altered by customers. We can provide no assurance as to
the profitability of our contracts reflected in backlog.

 

The Dalrada Precision Manufacturing segment has generated a backlog
of approximately $900,000,000 over a seven-year period with approximately $40,000,000 within the initial twelve-month period.

 

Operating Expenses

 

Total Operating Expenses increased to $30,019,876,
or 43.5%, compared to last year’s expenses of $20,941,591.

 

Corporate

 

Total Corporate expenses increased to $11,660,710,
or 7.5%, compared to last year’s expenses of $10,849,022.

 

The Corporate segment’s Selling, general
and administrative (“SG&A”) expenses consist of the following:

 

  · Employee compensation and benefits decreased by $604,188, or 11.8% from the prior year and is primarily a result of the Company allocating resources from the Corporate segment to each specific segment; shared resources across the four other business segments were included in the Corporate segment in the prior year.  Additionally, the Corporate segment began making cost cuts through employee compensation during Q4 2023.
     
  · Legal and professional fees decreased by $838,306, or 45.3% from the prior year.  The reduction was primarily a result of $230,400 associated with convertible debts issued in the prior year.  During the current year, the company began cutting costs in professional fees and incurred less legal fees.
     
  · Sales and marketing costs decreased by $213,098, or 74.2% from the prior year due to reduced costs associated with third party investor relations, paid media, and content creation expenses.  The Company’s internal marketing generates most of the sales and marketing services which is included in the employee compensation and benefits expenses.
   

 

  · Other general and administrative costs for general corporate expenses, including information technology, rent, travel, and insurance increased by $977,394, or 121.6% from the prior year and is a result increases in travel expenses, rent expense,
computer software expenses, and management fees.

 

 

 

 

  12  

 

 

Interest Expense increased by $1,249,204 or 95.8%
from the prior year as a result of increases in related party debt as well as PPP loans and convertible debt issued in prior years. See
“Note 7. Notes Payable” to our audited consolidated financial statements included in this Annual Report on Form 10-K for more
information regarding our outstanding debt.

 

Stock-based compensation includes expenses related
to equity awards issued to employees and non-employee directors. Stock-based compensation increased by $1,249,886, or 45.1% from the prior
year. See “Note 12. Stock-Based Compensation” to our audited consolidated financial statements included in this Annual Report
on Form 10-K for more information regarding our stock-based compensation.

 

Genefic

 

Total Genefic expenses increased to $11,468,627, or 86.5%, compared
to last year’s expenses of $6,147,976, and includes a $433,556 loss on impairment.

 

The Genefic segment’s Selling, general and
administrative (“SG&A”) expenses consist of the following:

 

  · Employee compensation and benefits increased by $1,646,077, or 220.1% from the prior year and a result of growth of the health-related business of the Genefic segment and the Company allocating resources from the Corporate segment to each specific segment; shared resources across the four other business segments were included in the Corporate segment in the prior year.  
     
  · Legal and Professional Fees increased by $1,101,256, or 81.1% from the prior year and primarily a result of the lawsuit with Vivera Pharmaceuticals.
     
  · Sales and marketing costs decreased by $185,003, or 79.8% from the prior year due to reduced costs associated with third party advertising, paid media, and content creation expenses.  The Company’s internal marketing generates most of the sales and marketing services which is included in the Corporate segment employee compensation and benefits expenses.
     
  · Other general and administrative costs increased by $2,543,073, or 70.8% from the prior year and is a result of expansion of the diagnostic and pharmacy subsidiaries where certain business opportunities included large overhead expenses.

 

Dalrada Precision Manufacturing

 

Total Dalrada Precision Manufacturing expenses increased to $4,136,885,
or 41.0%, compared to last year’s expenses of $2,933,732.

 

The Dalrada Precision Manufacturing Segment’s
Selling, general and administrative (“SG&A”) expenses consist of the following:

 

  · Employee compensation and benefits increased by $1,148,369, or 356.7% from the prior year and a result of growth of the precision manufacturing business of the Dalrada Precision Manufacturing segment and the Company allocating resources from the Corporate segment to each specific segment; shared resources across the four other business segments were included in the Corporate segment in the prior year.  
     
  · Legal and Professional
Fees
increased by $484,698, or 73.7% from the prior year and is a result of consulting fees related to the growth in
manufacturing of precision parts in Asia and establishing third-party manufacturing capabilities of the Likido®ONE in the
United States. The increase in legal fees was a result of the settlement Likido Ltd.’s lawsuit with MAPtech Packaging, Inc.
Pursuant to the settlement, the Company shall pay the sum of $558,252 in damages, legal costs, and reimbursement for arbitration
fees and expenses paid on account by MAPtech.
     
  · Sales and marketing
costs decreased by $19,533, or 53.7% from the prior year due to reduced costs associated with third party advertising, paid media,
and content creation expenses. The Company’s internal marketing generates most of the sales and marketing services which is
included in the Corporate segment employee compensation and benefits expenses.
     
  · Other general and administrative costs increased by $246,616, or 19.6% from the prior year and is a result of an increase in travel, trade shows and other overhead expenses required for the expansion in the Precision Parts and Ignite businesses.

 

 

 

 

  13  

 

 

Dalrada Energy Services

 

Total Dalrada Energy Services expenses increased
to $1,969,829, or 1,515.9%, compared to last year’s expenses of $121,904, and is a result of a full year of operations for the Dalrada
Energy Services subsidiary and the acquisition of Bothof Brothers.

 

The Dalrada Energy Services Segment’s Selling,
general and administrative (“SG&A”) expenses consist of the following:

 

  · Employee compensation
and benefits
increased to $484,719 as the energy segment continued to grow during the year.  The employee resources
were focused on the development of the current projects and building a future pipeline.  Additionally, Company allocated
resources from the Corporate segment to each specific segment. The Dalrada Energy Services segment did not have employee
compensation and benefits expense during the prior year.
     
  · Legal and Professional Fees increased by $452,869, or 377.3% from the prior year and is a result of the growth of the energy segment throughout the year.  Professional fees included services for management fees and other services specific to the energy industry.
     
  · Sales and marketing
costs increased to $12,599. The Company’s internal marketing generates most of the sales and marketing services which is
included in the Corporate segment employee compensation and benefits expenses. The Dalrada Energy Services segment did not have
sales and marketing costs during the prior year.
     
  · Other general and administrative costs increased to $897,738 from the prior year and is a result of management fees, travel and other general overhead costs associated with Dalrada Energy Services’ energy upgrade business and Bothof Brothers Contracting.

 

Dalrada Technologies

 

Total Dalrada Technologies expenses decreased
to $783,825, or 11.8%, compared to last year’s expenses of $888,957.

 

The Dalrada Technologies segment’s Selling,
general and administrative (“SG&A”) expenses consist of the following:

 

  · Employee compensation and benefits increased by $17,435, or 5.4% from the prior year and is a result of employee fluctuations and wage inflation.
      
  · Legal and Professional Fees decreased by $198,198, or 59.0% from the prior year and is a result of a reduced third-party engineering fees related to its projects.
     
  · Sales and marketing costs decreased by $3,797, or 71.3% from the prior year and is a result of reduced third-party advertising and marketing costs.
     
  · Other general and administrative costs increased by $79,428, or 35.3% and is a result of increases in information technology, rent, travel, and insurance costs.

 

Other Income (Expense)

 

Other Income (Expense) decreased by $1,336,262
or 133.1% from a $1,004,026 Other Expense in the prior year to a $332,236 Other Income in the current year. The change in Other Expense
was a result of interest incurred of $2,549,309 related to additional related party debt, EIDL loans, and convertible debt (See “Note
7. Notes Payable” to our audited consolidated financial statements included in this Annual Report on Form 10-K for more information
regarding our outstanding debt) which is offset by a $2,090,978 “Gain on expiration of accrued payroll taxes” due to quarterly
tax liabilities that expired during fiscal 2023, $500,000 related to the sale of the Dalrada Energy Services intellectual property, and
a $585,411 change in the fair value of contingent liability.

 

 

 

  14  

 

 

Net Income (Loss)

 

Net Loss for the year ended June 30, 2023, was
$20,627,721 compared to a Net loss of $11,571,783 during the year ended June 30, 2022

 

Liquidity and Capital Resources

 

As of June 30, 2023, the Company had current assets
of $9,817,045 and current liabilities of $10,019,465 compared with current assets of $9,563,566 and current liabilities of $20,416,745
at June 30, 2022. The decrease in the working capital deficit is primarily a result of the Company converting $33,859,544 of related party
debt during the year. The continuation of the Company as a going concern is dependent upon the successful financing through equity and/or
debt investors and growing the subsidiaries anticipated to be profitable while reducing investments in areas that are not expected to
have long-term benefits.

 

The Company anticipates an increase in sales of
Likido’s Likido®ONE heat pump through its current and future customer base. Furthermore, the United States General Services
Administration (GSA) and the Department of Energy (DOE) have chosen the Company’s Likido®ONE heat pump to help reduce greenhouse
emissions from commercial buildings through high performance, low-carbon solutions set forth by the Green Proving Ground (GPG) program.

 

The Company is owed a material amount of account
receivable from insurance providers related to the COVID-19 testing services. Furthermore, the Company wrote down $2,945,387 of receivables
during the year ended June 30, 2023 which it is actively working to recoup through its third-party billing company.

 

Watson obtained additional accreditations including
the Healthcare Merchant Accreditation from the National Association of Boards of Pharmacy (NABP) and the Specialty Pharmacy Accreditation
and Mail Service Pharmacy Accreditation from the Utilization Review Accreditation Commission (URAC) during the year ended June 30, 2023,
and will lead to larger sales opportunities throughout the United States.

 

Additional sales are expected through the Company’s
increased Precision Parts sales channels, expansion of Prakat’s technology services, and IHG’s increased educational footprint
through launching the LVN program. These consolidated financial statements do not include any adjustments to the recoverability and classification
of recorded asset amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going
concern.

 

Cash Flows

 

    Year Ended  
    June 30,  
    2023     2022  
Net cash used in operating activities   $ (4,612,798 )   $ (10,349,808 )
Net cash used in investing activities     (1,063,427 )     (574,040 )
Net cash provided by financing activities     5,717,144       11,668,585  
Net change in cash during the period, before effects of foreign currency   $ 40,919     $ 744,737  

 

Cash flow from Operating Activities

 

During the year ended June 30, 2023, the Company
used $4,612,798 of cash for operating activities compared to $10,349,808 used during the year ended June 30, 2022. The decrease in the
use of cash for operating activities was primarily due to an overall increase in direct funding from related parties.

  

 

 

 

  15  

 

 

Cash flow from Investing Activities

 

During the year ended June 30, 2023, the Company
used $1,063,427 of cash for investing activities compared to $574,040 used during the year ended June 30, 2022. The increase in the use
of cash for investing activities was due to the purchase of property plant and equipment.

 

Cash flow from Financing Activities

 

During the year ended June 30, 2023, the Company
received $5,717,144 of cash for financing activities compared to $11,668,585 received during the year ended June 30, 2022. The decrease
in financing activities was primarily due to the direct funding received from related party notes payable to finance operating activities.

 

Off-Balance Sheet Arrangements

 

We have no off-balance sheet arrangements that
have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, Revenues
or expenses, results of operations, liquidity, capital expenditures or capital resources.

 

Subsequent Events

 

On July 1, 2023, Bothof Brothers signed a lease
for 12,100 square feet of warehouse space in Escondido, California related to its construction business. The base monthly lease cost is $11,425 and expires on September 30, 2025.

 

On July 25, 2023, Genefic Inc. (“Genefic”),
entered into an agreement with OnPoint LTB, LLC (“Lender”), for a credit line and funding of up to $2,000,000. The terms of
the credit line include a 24-month term loan, with interest only for 6 months, then amortizing over 18 months down to 50%, with 50% of
the balance due at the end of term. Interest is fixed at 20% per annum, with an origination fee of $20,000 which is added to the loan
balance. Genefic borrowed the first installment of $1,200,000 at the time of closing. As part of the loan origination fee, Dalrada Financial
Corporation is to issue 500,000 shares of its common stock. In addition, Genefic will issue cashless warrants equal to one percent of
Genefic, if and when Genefic engages in a public offering of stock, prior to the maturity date of the loan transaction. The cashless warrants
will have a strike price of $0.50. The transaction includes a debt discount of $100,821.

 

On July 31, 2023, the Company issued 109,637 shares
of common stock pursuant to the Stock Purchase Agreement between Dalrada Financial Corporation and Prakat Solutions Inc.

 

On August 08, 2023, the Company’s subsidiary,
Dalrada Technology Spain S.L., entered into an agreement, which was Amended August 30, 2023, with Morocco-based global distributor, Crown
Glory Holding to build and install a minimum of 4,500 energy efficient commercial heat pumps over the course of seven years. With the
agreement, Crown Glory Holding also becomes the exclusive distributor of the Company’s heat pumps for the continent of Africa and
select neighboring countries.

 

On August 29, 2023, the Company’s subsidiary,
Dalrada Technology Spain S.L., entered into an agreement which was Amended August 30, 2023, with France-based JBS Consulting, to distribute
a minimum of 2,300 energy efficient commercial heat pumps over the course of five years. The agreement calls for 150 of the commercial
heat pumps to be installed and operational within the first 12 months, commencing in October of 2023, with increased numbers of the high-functioning
machines installed each year until the contract is fully satisfied.

 

On September 6, 2023, the Dalrada Board of Directors
approved 15,861,000 warrants to various Board of Director members, employees and consultants. The total stock-based compensation expense
is $2,064,699.

 

On September 18, 2023, the Company appointed Heather
McMahon to the Board of Directors.

 

On September 27, 2023, the Company issued 125,000
shares of common stock as part of the consideration for the acquisition of Watson RX Solution, Inc.

 

On October 2, 2023, Genefic borrowed the second
installment of the OnPoint LTB, LLC loan of $800,000. The second installment included a loan origination fee of $5,000 and 500,000 of
Dalrada Financial Corporation common stock. The transaction includes a debt discount of $154,492. 

 

On October 5, 2023, Genefic acquired Diller Pharmacy
LLC for the consideration of $135,000 in cash and assuming its lease, which includes a monthly lease cost of $325 and expires on February
28, 2025.

 

 

  16  

 

 

Critical Accounting Policies

 

Our consolidated financial statements and accompanying
notes have been prepared in accordance with accounting principles generally accepted in the United States of America and applied on a
consistent basis. The preparation of financial statements in conformity with accounting principles generally accepted in the United States
of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure
of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during
the reporting periods.

 

We regularly evaluate the accounting policies
and estimates that we use to prepare our consolidated financial statements. A complete summary of these policies is included in note (1)
of the notes to our consolidated financial statements. In general, management’s estimates are based on historical experience, on information
from third party professionals, and on various other assumptions that are believed to be reasonable under the facts and circumstances.
Actual results could differ from those estimates made by management.

 

Accrued Payroll Taxes

 

The total balance for Federal Accrued Payroll
Taxes is accumulated on a quarterly basis beginning on their respective quarterly filing dates. Accrued Interest is compounded daily at
an Effective Annual Interest Rate of approximately seven percent. The individual quarterly sub-totals have a calculated expiration date
of ten years according to the Internal Revenue Service (“IRS”) statute of limitations. This timeline can be extended because
of bankruptcy or other legal action that is filed by the Company (Code 520 per IRS Federal Account Transcripts). Code 520 effectively
stops the clock for the Statute of limitations until the bankruptcy or other legal action has been removed (Code 521 per IRS Federal Account
Transcripts). In addition to the number of days between Code 520 and 521, every Code 520 automatically extends the IRS Statute of limitations
by 30 days. As the quarterly sub-totals surpass their respective “Calculated Expiration Date” the Company removes the liability
from the Consolidated Balance Sheets and an equivalent amount is recognized as “Gain on expiration of accrued payroll taxes”
on the Consolidated Statements of Operations and Comprehensive Loss. The amount owing may be subject to additional late filing fees and
penalties that are not quantifiable as at the date of these consolidated financial statements.

 

Revenue Recognition

 

The Company recognizes and accounts for revenue
in accordance with Accounting Standards Codification (“ASC”) 606 as a principal on the sale of goods and services. Pursuant
to ASC 606, revenue is measured based on a consideration specified in a contract with a customer, and excludes any sales incentives and
amounts collected on behalf of third parties. The Company recognizes revenue when it satisfies its performance obligation by transferring
control over a product or service to a customer.

  

Use of Estimates

 

Our consolidated financial statements and accompanying
notes have been prepared in accordance with accounting principles generally accepted in the United States of America and requires management
to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities
at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. The
Company regularly evaluates estimates and assumptions related to the revenue, valuation of inventory, valuation of acquired assets and
liabilities, variables used in the computation of share-based compensation, litigation, and evaluation of goodwill and intangible assets
for impairment.

 

The Company bases its estimates and assumptions
on current facts, historical experience, and various other factors that it believes to be reasonable under the circumstances, the results
of which form the basis for making judgments about the carrying values of assets and liabilities and the accrual of costs and expenses
that are not readily apparent from other sources. The actual results experienced by the Company may differ materially and adversely from
the Company’s estimates. To the extent there are material differences between the estimates and the actual results, future results
of operations will be affected.

 

 

  17  

 

 

Stock-Based Compensation

 

The Company records stock-based compensation in
accordance with ASC 718, Compensation – Stock Compensation, using the fair value method. All transactions in which goods
or services are the consideration received for the issuance of equity instruments are accounted for based on the fair value of the consideration
received or the fair value of the equity instrument issued, whichever is more reliably measurable. Equity instruments issued to employees
and the cost of the services received as consideration are measured and recognized based on the fair value using quoted market prices
of the equity instruments issued.

  

Business
Combination

 

ASC 805,
Business Combinations (“ASC 805”), applies the acquisition method of accounting for business combinations to all acquisitions
where the acquirer gains a controlling interest, regardless of whether consideration was exchanged. ASC 805 establishes principles and
requirements for how the acquirer: a) recognizes and measures in its financial statements the identifiable assets acquired, the liabilities
assumed, and any non-controlling interest in the acquiree; b) recognizes and measures the goodwill acquired in the business combination
or a gain from a bargain purchase; and c) determines what information to disclose to enable users of the financial statements to evaluate
the nature and financial effects of the  business  combination. Accounting for acquisitions requires the Company to recognize,
separately from goodwill, the assets acquired, and the liabilities assumed at their acquisition-date fair values. Goodwill as of the acquisition
date is measured as the excess of consideration transferred and the net of the acquisition-date fair values of the assets acquired and
the liabilities assumed. While the Company uses its best estimates and assumptions to accurately value assets acquired and liabilities
assumed at the acquisition date, the estimates are inherently uncertain and subject to refinement. As a result, during the measurement
period, which may be up to one year from the acquisition date, the Company may record adjustments to the assets acquired and liabilities
assumed with the corresponding offset to goodwill. Upon the conclusion of the measurement period or final determination of the values
of assets acquired or liabilities assumed, whichever comes first, any subsequent adjustments are recorded with a corresponding gain or
loss being recognized in the Consolidated Statements of Operations.

 

Goodwill and Intangible Assets

 

The Company accounts for goodwill and intangible
assets in accordance with ASC 350, Intangibles – Goodwill and Other (“ASC 350”). ASC 350 requires that goodwill and
other intangibles with indefinite lives should be tested for impairment annually or on an interim basis if events or circumstances indicate
that the fair value of an asset has decreased below its carrying value.

 

Goodwill is tested for impairment at the reporting
unit level (operating segment or one level below an operating segment) on an annual basis (June 30 for the Company) and between annual
tests if an event occurs or circumstances change that would more likely than not reduce the fair value of a reporting unit below its carrying
value. The Company considers its market capitalization and the carrying value of its assets and liabilities, including goodwill, when
performing its goodwill impairment test. When conducting its annual goodwill impairment assessment, the Company initially performs a qualitative
evaluation of whether it is more likely than not that goodwill is impaired. If it is determined by a qualitative evaluation that it is
more likely than not that goodwill is impaired, the Company then applies a two-step impairment test. The two-step impairment test first
compares the fair value of the Company’s reporting unit to its carrying or book value. If the fair value of the reporting unit exceeds
its carrying value, goodwill is not impaired and the Company is not required to perform further testing. If the carrying value of the
reporting unit exceeds its fair value, the Company determines the implied fair value of the reporting unit’s goodwill and if the carrying
value of the reporting unit’s goodwill exceeds its implied fair value, then an impairment loss equal to the difference is recorded in
the Consolidated Statements of Operations. The Company recorded an impairment of goodwill in the amount of $433,556 and $218,308 during
the years ended June 30, 2023 and 2022, respectively.

 

 

 

 

  18  

 

 

An intangible asset is an identifiable non-monetary
asset without physical substance. Such an asset is identifiable when it is separable, or when it arises from contractual or other legal
rights. Separable assets can be sold, transferred, licensed, etc. Examples of intangible assets include computer software, licenses, trademarks,
patents, films and copyrights. The Company’s intangible assets are finite lived assets and are amortized on a straight-line basis
over the estimated useful lives of the assets.

 

Purchase Price Allocation

 

Upon the completion of a business combination,
the consideration transferred as well as the assets and liabilities acquired must be recorded at their acquisition date fair values. Upon
identification of the acquirer and determination of the acquisition date, business combinations are accounted for through the preparation
of a Purchase Price Allocation (PPA). We take into consideration the five steps when completing a PPA:

Step 1: Determine the fair value of consideration
paid;

Step 2: Revalue all existing assets and liabilities
(excluding intangible assets and goodwill which are addressed in step 3 to 5 below) to their acquisition date fair values;

Step 3: Identify the intangible assets acquired;

Step 4: Determine the fair value of identifiable
intangible assets acquired; and,

Step 5: Allocate the remaining consideration to
goodwill and assess the reasonableness of the overall conclusion

  

Related Party Transactions

 

Related party transactions are conducted with
parties with which the Company has a close association, such as majority owned subsidiaries, its executive, managers, and their families.
The types of transactions that can be conducted between related parties are many, such as sales, asset transfers, leases, lending arrangements,
guarantees, allocations of common costs, and the filing of consolidated tax returns. The Company discloses any transaction that would
impact the decision making of the users of its consolidated financial statements. This involves the following disclosures:

 

  · General. The Company discloses all material related party transactions, including the nature of the relationship, the nature of the transactions, the dollar amounts of the transactions, the amounts due to or from related parties.
  · Receivables. The Company separately discloses any receivables from officers, employees, or affiliated entities.

 

Recently Issued Accounting Pronouncements

 

In August 2020, the Financial Accounting Standards
Board (“FASB”) issued Accounting Standards Update (“ASU”) 2020-06, Accounting for Convertible Instruments and
Contracts in an Entity’s Own Equity
, as part of its overall simplification initiative to reduce costs and complexity of applying
accounting standards while maintaining or improving the usefulness of the information provided to users of financial statements. Among
other changes, the new guidance removes from GAAP separation models for convertible debt that require the convertible debt to be separated
into a debt and equity component, unless the conversion feature is required to be bifurcated and accounted for as a derivative or the
debt is issued at a substantial premium. As a result, after adopting the guidance, entities will no longer separately present such embedded
conversion features in equity, and will instead account for the convertible debt wholly as debt. The new guidance also requires use of
the “if-converted” method when calculating the dilutive impact of convertible debt on earnings per share, which is consistent
with the Company’s current accounting treatment under the current guidance. The guidance is effective for financial statements issued
for fiscal years beginning after December 15, 2021, and interim periods within those fiscal years, with early adoption permitted, but
only at the beginning of the fiscal year. The Company adopted the guidance on July 1, 2022.

 

 

 

  19  

 

 

In October 2021, the FASB issued ASU 2021-08 –
Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers (“ASU 2021-08”).
Under current accounting standards, contract assets and contract liabilities acquired in a business combination are to be recorded at
fair value using the ASC 805 measurement principle. ASU 2021-08 requires the acquirer to recognize and measure contract assets and contract
liabilities acquired in a business combination in accordance with Topic 606: Revenue from Contracts with Customers as if the acquirer
had originated the contracts rather than at fair value. ASU 2021-08 is effective for fiscal years beginning after December 15, 2022, with
early adoption permitted. The Company elected to early adopt ASU 2021-08 on a prospective basis as of July 1, 2021. The election to use
practical expedients allowed under ASU 2021-08 will be applied on an acquisition-by-acquisition basis. There was no impact to the Company’s
consolidated financial statements as of the adoption date.

 

The FASB and the SEC have issued certain other
accounting pronouncements as of June 30, 2023 that will become effective in subsequent periods; however, management does not believe that
any of these pronouncements would have significantly affected the Company’s financial accounting measurements or disclosures had
they been in effect during the periods for which financial statements are included in this annual report, nor does management believe
those pronouncements would have a significant effect on the Company’s future financial position or results of operations 

 

Contractual Obligations

 

We are a smaller reporting company as defined
by Rule 12b-2 of the Securities Exchange Act of 1934 and are not required to provide the information under this item.

 

ITEM 7A. Quantitative and Qualitative Disclosures
about Market Risk

 

Not applicable to smaller reporting companies.

 

 

 

 

 

 

 

 

 

  20  

 

 

Item 8. Financial Statements

 

 

DALRADA FINANCIAL CORPORATION

 

Consolidated Financial Statements

 

For the Years Ended June 30, 2023 and 2022

 

 

 

 

Report of Independent Registered Public Accounting Firm F-1
Consolidated Balance Sheets F-5
Consolidated Statements of Operations and Comprehensive Loss F-6
Consolidated Statements of Stockholders’ Equity (Deficit) F-7
Consolidated Statements of Cash Flows F-9
Notes to the Consolidated Financial Statements F-10

 

 

 

 

 

 

 

  21  

 

 

 

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING
FIRM (PCAOB ID N0. 324)

 

To the Board of Directors and

Stockholders of Dalrada Financial Corporation

 

Opinion on the Consolidated Financial Statements

We have audited the accompanying consolidated
balance sheet of Dalrada Financial Corporation and its subsidiaries (the “Company”) as of June 30, 2023, the related consolidated
statements of operations and comprehensive loss, changes in shareholders’ equity (deficit), and cash flows for the year ended June
30, 2023, and the related notes to the consolidated financial statements (collectively, referred to as the “consolidated financial
statements”). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position
of the Company as of June 30, 2023, and the results of its operations and its cash flows for year then ended, in conformity with accounting
principles generally accepted in the United States of America.  

 

Going Concern

The accompanying consolidated financial statements
have been prepared assuming that the Company will continue as a going concern. As discussed in Note 1 to the consolidated financial statements,
the Company has suffered recurring losses from operations, negative cash flows from operating activities and continues to have a working
capital deficit. This raises substantial doubt about the Company’s ability to continue as a going concern. Management’s plans
in regard to these matters are also described in Note 1. The consolidated financial statements do not include any adjustments that might
result from the outcome of this uncertainty.

 

Basis for Opinion

These consolidated financial statements are the
responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s consolidated financial
statements based on our audit. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States)
(“PCAOB”) and are required to be independent with respect to the Company in accordance with U.S. federal securities laws and
the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

 

We conducted our audit in accordance with the
standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated
financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we
engaged to perform, an audit of its internal control over financial reporting. As part of our audit, we are required to obtain an understanding
of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company’s
internal control over financial reporting. Accordingly, we express no such opinion.

 

Our audit included performing procedures to assess
the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures
that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the
consolidated financial statements. Our audit also included evaluating the accounting principles used and significant estimates made by
management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audit provides
a reasonable basis for our opinion.

 

Critical Audit Matters

The critical audit matters communicated below
are matters arising from the current period audit of the consolidated financial statements that were communicated or required to be communicated
to the audit committee and that: (1) relates to accounts or disclosures that are material to the consolidated financial statements and
(2) involved our especially challenging, subjective, or complex judgments. The communication of the critical audit matters does not alter
in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit
matter below, providing separate opinions on the critical audit matters or on the accounts or disclosures to which it relates.  

 

 

 

 

 

  F-1  

 

 

Impairment Assessment of Goodwill

Description of the Matter:

As discussed in Notes 2, 3, 4, 5, 11, 12 and
16 to the consolidated financial statements, the Company had a number of business combinations during the current and prior fiscal years
that led to the recording of goodwill. Goodwill is tested for impairment at least annually in accordance with the provisions of ASC No.
350, “Intangibles Goodwill and Other” (“ASC No. 350”). We identified the impairment assessment of the Company’s
goodwill acquired in these acquisitions as a critical audit matter as of June 30, 2023. Auditing the Company’s impairment tests
was complex and highly judgmental because (i) there was significant judgment used by management to develop the fair value measurement,
which led to a high degree of audit judgment and subjectivity in performing procedures relating to fair value measurement; and (ii) there
was significant effort in performing procedures to evaluate the reasonableness of the fair value measurement and significant assumptions
and projections used by management.

 

How We Addressed the Matter in our Audit:

Addressing the matter involved performing procedures
and evaluating audit evidence in connection with forming our overall opinion on the consolidated financial statements. To test the potential
impairment of the Company’s goodwill, our audit procedures included, among others, testing management’s application of the
relevant accounting guidance, and testing of the significant assumptions used by the Company to develop forecasted results for the reporting
unit, including projected revenue growth and operating margins. We also assessed the historical accuracy of management’s estimates,
as well as performed a sensitivity analysis of significant assumptions to evaluate the changes in the fair value of the reporting units
that would result from changes in the assumptions. We compared the significant assumptions to current and past industry, market and economic
trends. Additionally, we tested the completeness and accuracy of the underlying data supporting the significant assumptions and estimates

 

Revenue Recognition

Description of the Matter:

As disclosed in Note 2, 9 and 13, the Company
follows the guidance provided in ASC 606, Revenue from Contracts with Customers, and recognizes revenue when or as the Company
satisfies a customer agreement performance obligation by transferring control of a product or service to a customer, in an amount that
reflects the consideration the Company expects to receive in exchange for those products or services. A presumption of fraud risk exists
related to revenue recognition and judgment is exercised by the Company in determining revenue recognition for each performance obligation
within their customer agreements. We identified the Company’s recording of revenues as a critical audit matter because there was
significant judgment applied by management in its determination of the appropriate revenue recognition criteria, including assessing the
indicators for when control is transferred to the customer, assessing management’s evaluation and allocation of the standalone transaction
prices to the performance obligations, as well as management’s assessment of the impact on revenue recognition of non-standard terms
and conditions. In turn, this led to a high degree of auditor judgment, subjectivity and effort in performing audit procedures and evaluating
the results of those procedures.

 

How We Addressed the Matter in our Audit:

Addressing the matter involved performing procedures
and evaluating audit evidence in connection with forming our overall opinion on the consolidated financial statements. Our principal audit
procedures related to the Company’s revenue recognition included gaining an understanding of internal controls related to revenue
recognition including management’s controls related to the evaluation of performance obligations and the allocation of the total
contract consideration to these performance obligations noted in their customer agreements. We evaluated management’s revenue recognition
policies and practices including the reasonableness of management’s judgments and assumptions relating to the timing of revenue
recognition of those performance obligations. In addition, we selected customer agreements and performed the following testing procedures:
1) Obtained and read the customer agreements or contracts for each selected agreement. 2) Evaluated and tested management’s identification
of significant terms for completeness, including the identification of distinct performance obligations. 3) Tested revenue contracts and
underlying support to evaluate appropriateness of management’s revenue recognition. 4) Tested the completeness and accuracy of management’s
calculation of revenue and associated timing of revenue recognized (i.e., revenue being recognized at a point in time vs over time). 5)
These procedures also included, among others, testing management’s process for developing estimates for contractual allowances and
project completion, including (i) evaluating the appropriateness of the methodology, (ii) testing the completeness and accuracy of the
historical contractual allowance and collection data from the Company’s billing system, which is an input to the methodology, and
(iii) evaluating the reasonableness of management’s assumptions used to estimate contractual allowances (net accounts), as well
as testing relevant inputs and project costs incurred used to develop estimates of project progress compared to the overall project budget.

 

We have served as the Company’s auditor
since 2023.

 

/s/ Macias Gini & O’Connell LLP

Melville, New York

October 19, 2023

PCAOB No. 324

 

 

  F-2  

 

 

 

REPORT OF INDEPENDENT
REGISTERED PUBLIC ACCOUNTING FIRM

 

To the Board of Directors and
Stockholders of Dalrada Financial Corporation

 

Opinion on the Financial
Statements

We have audited the accompanying
consolidated balance sheet of Dalrada Financial Corporation and subsidiaries (collectively the “Company”) as of June 30, 2022,
the related consolidated statements of operations, stockholders’ deficit and cash flows for the year then ended, and the related
notes (collectively referred to as the “consolidated financial statements”). In our opinion, the consolidated financial statements
present fairly, in all material respects, the consolidated financial position of the Company as of June 30, 2022, and the results of their
operations and their cash flows for the year then ended, in conformity with accounting principles generally accepted in the United States
of America.

 

Basis for Opinion

These consolidated financial
statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s
consolidated financial statements based on our audit. We are a public accounting firm registered with the Public Company Accounting Oversight
Board (United States) (“PCAOB”) and are required to be independent with respect to the Company in accordance with the U.S.
federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

 

We conducted our audit
in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance
about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. The Company is not
required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audit we are
required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the
effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion.

 

Our audit included performing
procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing
procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures
in the consolidated financial statements. Our audit also included evaluating the accounting principles used and significant estimates
made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audit
provides a reasonable basis for our opinion.

 

Going Concern

The accompanying consolidated
financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 1 to the consolidated
financial statements, the Company has had recurring losses, used cash flows from operating activities and has a significant working capital
deficit, which raises substantial doubt about its ability to continue as a going concern. Management’s plans in regard to these
matters are also described in Note 1. The consolidated financial statements do not include any adjustments that might result from the
outcome of this uncertainty.

 

Critical Audit Matters

The critical audit matters
communicated below is a matter arising from the current period audit of the consolidated financial statements that was communicated or
required to be communicated to the audit committee and that: (1) relates to accounts or disclosures that are material to the consolidated
financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of the critical
audit matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating
the critical audit matter below, providing separate opinions on the critical audit matters or on the accounts or disclosures to which
it relates.

 

 

 

  F-3  

 

 

Related Party Transactions including Revenue Recognition

Description of the Matter:

As discussed in Notes
2, 4, 7, 8, 9, 10, 11, 12 and 14 to the consolidated financial statements, the Company has significant related party transactions involving
revenue, accounts receivable, accounts payable, loans payable, advances, and expenses paid by and to multiple related parties. Our auditing
of management’s identification of related parties and the related transactions including recognition of revenue was complex and
is based on a thorough understanding the Company’s related party relationships, contracts, and business activities. These were the
principal considerations that led us to determine this as a critical audit matter.

 

How We Addressed the
Matter in our Audit:

We evaluated the controls
over the Company’s identification of, and recording of related party transactions, and of the revenue recognition process, including
walkthroughs of internal controls. We confirmed certain balances and transactions with related parties. To evaluate the related party’s
satisfaction of performance obligations, our audit procedures included, among others, reviewing contracts and evaluating management’s
assumptions used to determine the distinct performance obligations, and reviewing the branding work performed by the Company for various
products. In addition, to identify undisclosed related party transactions we performed the following: 1) made inquiries of management
and other individuals throughout the Company; 2) obtained a selection of expenses and reviewed for related party indicators; 3) reviewed
public filings and other online information available; 4) confirmed with the transfer agent regarding significant shareholders; and 5)
related procedures performed in other parts of the audit engagement.

 

Revenue Recognition

Description of the Matter:

As disclosed in Note
2, 9, and 13, the Company recognizes revenue when or as the Company satisfies a customer agreement performance obligation by transferring
control of a product or service to a customer, in an amount that reflects the consideration the Company expects to receive in exchange
for those products or services. In determining revenue recognition for certain customer agreements, significant judgment was exercised
by the Company, and included the following: 1) An assessment of the products and services promised in contracts or customer agreements,
and the identification of a performance obligation for each promise to transfer to the customer a product or service that is distinct.
2) Determination of relative standalone selling price for distinct performance obligations. 3) The timing of product or service delivery
for performance obligations. 4) Net revenues and accounts receivable recognized from healthcare insurers and government payers consist
of amounts billed net of contractual allowances for differences between amounts billed and the estimated consideration the Company expects
to receive from such payers, which considers historical denial and collection experience and, additionally for healthcare insurers, the
terms of the Company’s contractual arrangements. As disclosed by management, the process for estimating revenues and the ultimate
collection of receivables associated involves significant assumptions and judgments. Given these factors, the related audit effort in
evaluating management’s judgments in determining revenue recognition for these customer agreements was extensive, which led us to
determine this as a critical audit matter.

 

How We Addressed the
Matter in our Audit:

Our principal audit procedures
related to the Company’s revenue recognition for these customer agreements included an evaluation of the controls related to the
identification of distinct performance obligations and the determination of the timing of revenue recognition. We also evaluated management’s
significant accounting policies related to certain customer agreements. In addition, we selected customer agreements and performed the
following procedures: 1) Obtained and read the customer agreements or contracts for each selected agreement. 2) Evaluated and tested management’s
identification of significant terms for completeness, including the identification of distinct performance obligations. 3) Evaluated the
appropriateness of management’s application of their accounting principles, in their determination of revenue recognition conclusions.
4) Tested the mathematical accuracy of management’s calculations of revenue and the associated timing of revenue recognized in the
consolidated financial statements. 5) These procedures also included, among others, testing management’s process for developing the estimate
for contractual allowances, including (i) evaluating the appropriateness of the methodology, (ii) testing the completeness and accuracy
of the historical contractual allowance and collection data from the Company’s billing system, which is an input to the methodology,
and (iii) evaluating the reasonableness of management’s assumptions used to estimate contractual allowances (net accounts receivable).

 

/s/ dbbmckennon

 

We have served as the
Company’s auditor from 2019 to 2022.

 

San Diego, California

October 31, 2022

PCAOB No. 3501

 

  F-4  

 

DALRADA FINANCIAL CORPORATION

Consolidated Balance Sheets

 

                 
    June 30,     June 30,  
    2023     2022  
Assets            
Current assets:                
Cash and cash equivalents   $ 812,806     $ 772,062  
Accounts receivable, net     4,453,104       6,406,555  
Accounts receivable, net – related parties     752,348       41,603  
Other receivables     376,604       288,655  
Inventories     2,078,692       1,624,621  
Prepaid expenses and other current
assets
    1,343,491       430,070  
Total current assets     9,817,045       9,563,566  
Long-term receivables     41,722       42,395  
Long-term receivables – related parties     1,173,893       1,209,103  
Property and equipment, net     1,476,082       1,076,412  
Goodwill     3,803,147       4,253,424  
Intangible assets, net     3,858,086       3,524,888  
Right-of-use asset, net     2,771,854       1,665,436  
Right-of-use asset, net – related party     2,227,286       1,087,256  
Total assets   $ 25,169,115     $ 22,422,480  
                 
Liabilities and Stockholders’ Equity (Deficit)                
Current liabilities:                
Accounts payable   $ 5,178,897     $ 2,331,919  
Accrued liabilities     1,084,008       1,799,404  
Accrued payroll taxes, penalties and interest           2,055,736  
Accounts payable and accrued liabilities – related
parties
    547,949       1,270,133  
Deferred revenue     1,337,259       720,923  
Notes payable, current portion     439,562       669,028  
Notes payable, current portion – related parties     251,605       9,269,377  
Convertible notes payable, net of debt discount           1,495,528  
Right-of-use liability     660,394       435,647  
Right-of-use liability – related
party
    519,791       369,050  
Total current liabilities     10,019,465       20,416,745  
Long-term payables     48,888       120,534  
Notes payable     1,011,395       479,001  
Notes payable – related parties     1,648,478       9,538,685  
Contingent consideration     4,285,389       4,870,800  
Right-of-use liability     2,160,834       1,231,691  
Right-of-use liability – related party     1,741,830       718,206  
Total liabilities     20,916,279       37,375,662  
                 
Commitments and contingencies (Note 14)            
                 
Stockholders’ deficit:                
Series I preferred stock, $0.01 par
value, 100,000 shares authorized, 35,108 and 0 shares issued and
outstanding as of June 30, 2023 and June 30, 2022, respectively
 
 
 
 
 
351
 
 
 
 
 
 
 
 
 
Series H preferred stock, $0.01 par
value, 15,002 and 0 shares authorized, issued and
outstanding as of June 30, 2023 and June 30, 2022, respectively
 
 
 
 
 
150
 
 
 
 
 
 
 
 
 
Series G preferred stock, $0.01 par
value, 100,000 shares authorized, 10,002 shares issued and outstanding as of both June 30, 2023 and June 30, 2022, respectively
 
 
 
 
 
100
 
 
 
 
 
 
 
100
 
 
Series F preferred stock, $0.01 par
value, 5,000 and 5,000 shares authorized, issued and
outstanding as of both June 30, 2023 and June 30, 2022, respectively
 
 
 
 
 
50
 
 
 
 
 
 
 
50
 
 
Common stock, $0.005 par value, 1,000,000,000
shares authorized, 88,699,139 and 72,174,620
shares issued and outstanding at June 30, 2023 and June 30, 2022, respectively
 
 
 
 
 
443,478
 
 
 
 
 
 
 
360,855
 
 
Common stock to be issued     192,925       1,066,925  
Additional paid-in capital     145,251,822       104,627,032  
Accumulated deficit     (141,729,009 )     (121,436,490 )
Accumulated other comprehensive
loss
    (50,848 )     (50,673 )
Total Dalrada Financial Corp’s
stockholders’ equity (deficit)
    4,109,019       (15,432,201 )
Noncontrolling
interests
    143,817       479,019  
Total stockholders’ equity (deficit)     4,252,836       (14,953,182 )
Total liabilities and stockholders’
equity (deficit)
  $ 25,169,115     $ 22,422,480  

 

(The accompanying notes are an integral part of
these consolidated financial statements)

  F-5  

 

 

DALRADA FINANCIAL CORPORATION

Consolidated Statements of Operations and Comprehensive
Loss

 

                 
    Year Ended  
    June 30,  
    2023     2022  
Revenues   $ 27,456,223     $ 17,864,557  
Revenues – related party     2,282,746       1,403,056  
Total revenues     29,738,969       19,267,613  
Cost of revenues     20,679,050       8,761,266  
Gross profit     9,059,919       10,506,347  
                 
Operating expenses:                
Selling, general and administrative (includes stock-based compensation of $4,022,656 and $2,772,770, respectively)     29,466,320       20,066,286  
Research and development     120,000       656,997  
Loss on impairment of goodwill     433,556       218,308  
Total operating expenses     30,019,876       20,941,591  
Loss from operations     (20,959,957 )     (10,435,244 )
                 
Other income (expense):                
Interest expense     (2,552,918 )     (1,303,714 )
Interest income     79,758       4,451  
Other income (expense)     722,620       308,534  
Gain on expiration of accrued tax liability     2,090,978        
Gain (loss) on foreign exchange     (8,202 )     (13,297 )
Total other income (expense), net     332,236       (1,004,026 )
Loss before taxes     (20,627,721 )     (11,439,270 )
Income taxes           132,513  
Net loss     (20,627,721 )     (11,571,783 )
                 
Other comprehensive loss                
Foreign currency translation     (175 )     (82,960 )
Comprehensive loss   $ (20,627,896 )   $ (11,654,743 )
                 
Net income (loss) attributable to noncontrolling interests     (335,202 )     2,526,533  
Net loss attributable to Dalrada Financial Corporation stockholders   $ (20,292,519 )   $ (14,098,316 )
                 
Net loss per common share to Dalrada stockholders – basic   $ (0.24 )   $ (0.20 )
Net loss per common share to Dalrada stockholders – diluted   $ (0.24 )   $ (0.20 )
                 
Weighted average common shares outstanding  — basic     83,761,903       72,217,851  
Weighted average common shares outstanding  — diluted     83,761,903       72,217,851  

 

(The accompanying notes are an integral part of
these consolidated financial statements)

 

 

 

 

 

  F-6  

 

 

DALRADA FINANCIAL CORPORATION

Consolidated Statements of Changes in Stockholders’
Equity (Deficit)

 

                                                                                         
    Preferred Stock                 Common      Preferred   
    Series I     Series H   Series G   Series F     Common Stock     Stock to     Stock to  
    Shares     Amount     Shares     Amount   Shares     Amount   Shares     Amount     Shares     Amount     be Issued     be Issued  
                                                                     
Balance at June 30, 2021       $         $         $     5,000     $ 50       73,838,662     $ 369,194       601,825        
Conversion of related party notes into preferred stock                                                               6,532,206  
Issuance of preferred stock                       10,002       100                                   (6,532,206 )
Common stock issued pursuant to acquisitions                                             1,850,000       9,252       290,100        
Joint ventures                                             250,000       1,250              
Reversal of shares previously issued to directors                                             (6,829,478 )     (34,147 )            
Common stock and warrants issued in connection with convertible note                                             192,000       930              
Common stock issued pursuant to conversion of note                                             373,436       1,876              
Stock-based compensation                                             2,500,000       12,500       175,000        
Net income (loss)                                                                
Foreign currency translation                                                                
Balance at June 30, 2022       $         $     10,002     $ 100     5,000     $ 50       72,174,620     $ 360,855     $ 1,066,925     $  
                                                                                         
Common stock issued for conversion of convertibles notes, accrued interest
and premium
                                            10,974,520       54,873              
Common stock issued pursuant to acquisitions                                             3,049,999       15,250       (699,000 )      
Common stock issued pursuant to consultant agreement                                             2,000,000       10,000              
Conversion of related party notes into preferred stock   35,108       351     15,022       150                                              
Warrants issued pursuant to acquisitions                                                                
Stock-based compensation                                             500,000       2,500       (175,000 )      
Net income (loss)                                                                
Foreign currency translation                                                                
Balance at June 30, 2023   35,108     $ 351     15,022     $ 150     10,002     $ 100     5,000     $ 50       88,699,139     $ 443,478     $ 192,925     $  

 

 

(Continued)

 

 

  F-7  

 

 

 

                                                 
                                   
    Additional          

Accumulated

Other

    Dalrada Financial Corp’s           Total  
    Paid-in     Accumulated     Comprehensive     Stockholders’     Noncontrolling     Stockholders’  
    Capital     Deficit     Income (Loss)     Deficit     Interests     Deficit  
                                     
Balance at June 30, 2021   $ 92,965,821     $ (107,338,174 )   $ 32,287     $ (13,368,997 )   $ (38,391 )   $ (13,407,388 )
Conversion of related party notes into preferred stock                                    
Issuance of preferred stock     6,532,106                   6,532,106             6,532,106  
Common stock issued pursuant to acquisitions     793,651                   1,093,003             1,093,003  
Joint ventures     57,310                   58,560       (2,009,123 )     (1,950,563 )
Reversal of shares previously issued to directors     19,321                   (14,826           (14,826
Common stock and warrants issued in connection with convertible note     1,541,765                   1,542,695             1,542,695  
Common stock issued pursuant to conversion of note     131,788                   133,664             133,664  
Stock-based compensation     2,585,270                   2,772,770             2,772,770  
Net income (loss)           (14,098,316 )           (14,098,316 )     2,526,533       (11,571,783 )
Foreign currency translation                 (82,960 )     (82,960 )           (82,960 )
Balance at June 30, 2022   $ 104,627,032     $ (121,436,490 )   $ (50,673 )   $ (15,432,201 )   $ 479,019     $ (14,953,182 )
                                                 
Common stock issued for conversion of convertibles notes, accrued interest
and premium
    1,392,615                   1,447,488             1,447,488  
Common stock issued pursuant to acquisitions     998,225                   314,475             314,475  
Common stock issued pursuant to consultant agreement     174,000                   184,000             184,000  
Conversion of related party notes into preferred stock     33,859,043                   33,859,544             33,859,544  
Warrants issued pursuant to acquisitions     5,751                   5,751             5,751  
Stock-based compensation     4,195,156                   4,022,656             4,022,656  
Net income (loss)           (20,292,519 )           (20,292,519 )     (335,202 )     (20,627,721 )
Foreign currency translation                 (175 )     (175 )           (175 )
Balance at June 30, 2023   $ 145,251,822     $ (141,729,009 )   $ (50,848 )   $ 4,109,019     $ 143,817     $ 4,252,836  

 

(The accompanying notes
are an integral part of these consolidated financial statements)

 

 

 

  F-8  

 

 

DALRADA FINANCIAL CORPORATION

Consolidated Statements of Cash Flows

 

                 
    Year Ended
    June 30,  
    2023     2022  
Cash flows from operating activities:                
Net loss   $ (20,627,721 )   $ (11,571,783 )
Adjustments to reconcile net loss to net cash used in operating activities:                
Depreciation and amortization     707,572       323,018  
Stock compensation     4,022,656       2,772,770  
Stock consideration issued to vendor     184,000        
Amortization of debt discount     1,224,472       554,970  
Convertible debt premium satisfied with common stock     200,000       20,000  
Change in fair value of contingent consideration     (270,936 )     (182,200 )
Bad debt expense     4,783,357       1,659,559  
Loss on impairment of goodwill     433,556       218,308  
Gain on expiration of accrued tax liability     (2,090,978 )      
Changes in operating assets and liabilities, net of amounts acquired or assumed in connection with acquisition:                
Accounts receivable     (3,897,875 )     (7,383,296 )
Other receivables     (60,660 )     (221,327 )
Inventories     (454,071 )     (608,657 )
Prepaid expenses and other current assets     (722,147 )     (137,767 )
Long-term receivables     35,883       (1,251,498 )
Accounts payable     2,822,813       1,116,618  
Long-term payables     (71,646 )     120,534  
Accounts payable and accrued liabilities – related parties     7,936,820       2,405,364  
Accrued liabilities     640,529       1,211,943  
Accrued payroll taxes, penalties and interest     35,242       102,712  
Deferred revenue     556,336       500,924  
Net cash used in operating activities     (4,612,798 )     (10,349,808 )
Cash flows from investing activities:                
Purchase of property and equipment     (693,201 )     (640,184 )
Purchase of intangibles     (470,680 )     (242,063 )
Acquisition of business, net of cash     100,454       308,207  
Net cash used in investing activities     (1,063,427 )     (574,040 )
Cash flows from financing activities:                
Proceeds from related party notes payable     6,757,688       11,492,218  
Proceeds from convertible notes payable           2,880,000  
Repayments of related party notes payable     350,028       (233,556 )
Repayments of convertible note payable     (1,680,000 )     (300,000 )
Distributions to noncontrolling interest           (2,120,308 )
Net proceeds (repayments) from notes payable     289,428       (34,943 )
Repurchase of common shares from subsidiary           (14,826 )
Net cash provided by financing activities     5,717,144       11,668,585  
Net change in cash and cash equivalents     40,919       744,737  
Effect of exchange rate changes on cash     (175 )     (82,960 )
Cash and cash equivalents at beginning of period     772,062       110,285  
Cash and cash equivalents at end of period   $ 812,806     $ 772,062  

 

 

 

 

  F-9  

 

 

Supplemental disclosure of cash flow information:                
Cash paid for income taxes   $ 139,941     $ 77,766  
Cash paid for interest   $ 9,048     $  
                 
Supplemental disclosure of non-cash investing and financing activities:                
Conversion of related party notes and interest into preferred stock   $ 33,859,544     $ 6,532,206  
Contribution of property and equipment into joint venture   $     $ 111,185  
Issuance of shares to joint venture partner   $     $ 58,560  
Conversion of accounts payable-related parties to note payable-related parties   $ 8,676,605     $ 181,744  
Common stock and warrants issued in connection with convertible note   $     $ 1,542,695  
Common stock issued pursuant to conversion of note, accrued interest and premium   $     $ 133,664  
Common stock issued pursuant to business combination   $ 314,475     $ 1,093,003  
Fair value of assets acquired and liabilities assumed in acquisition   $     $ 468,232  
Conversion of convertible note payable, accrued interest and premium into common stock   $ 1,447,488     $  
Increase in right-of-use asset and liability   $ 2,227,830     $  

 

(The accompanying notes are an integral part of
these consolidated financial statements)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

  F-10  

 

 

DALRADA FINANCIAL CORPORATION

Notes to the Consolidated Financial Statements

Years ended June 30, 2023, and 2022

 

 

1. Organization and Nature of Operations

 

Unless otherwise stated or the context
requires otherwise, references herein to the “Company,” “Dalrada,” “we,” “us,” and “our”
mean Dalrada Financial Corporation and its direct and indirect subsidiaries, and controlled and managed entities.

 

Dalrada Financial Corporation, (“Dalrada”),
was incorporated in September 1982 under the laws of the State of California. It was reincorporated in May 1983 under the laws of the
State of Delaware and reincorporated again on May 5, 2020, under the laws of the state of Wyoming. Dalrada Financial Corporation trades
under the symbol, OTCQB: DFCO.

 

Dalrada has five primary business divisions:
Genefic, Dalrada Energy Services, Dalrada Precision Manufacturing, Dalrada Technologies and Dalrada Corporate.
Dalrada’s global solutions directly address climate change, gaps in the health care industry, and technology needs that facilitate
a new era of human behavior and interaction and ensure a bright future for the world around us.

 

Genefic (formerly Dalrada Health)

 

Genefic, formerly named Dalrada Health,
delivers advanced health care solutions with dedicated products, services, and systems. From virus and disease screening capabilities
to pharmaceutical goods and holistic wellness clinics, this specialized division is committed to developing key health products, lifesaving
medications and building comprehensive systems to increase capability, strive to keep people healthy with the goals of improving their
quality of life and increasing their longevity– on a global level.

 

Empower
Genomics (“Empower”)
– Empower is Dalrada’s wholly owned diagnostic laboratory subsidiary which processes molecular
diagnostic and antibody tests to support the diagnosis of COVID-19 and the detection of immune response to the virus. Empower has built
up and maintained the testing capacity to handle surges in COVID-19 testing demands. Empower also offers genetic testing capabilities
including Pharmacogenomics, Nutraceutical, Nutrition/Diet DNA and Exercise/Fitness DNA tests.

 

Pala
Diagnostics (“Pala”)
– Pala is a joint venture diagnostic laboratory which processes both molecular diagnostic and antibody
tests to support the diagnosis of COVID-19 and the detection of immune response to the virus.

 

Solas
Corp. (“Solas”)
– Solas manages and oversees wellness clinics throughout Southern California including the Sòlas
Rejuvenation + Wellness clinics (“Sòlas”). Through advanced medical techniques and modern technology, Sòlas
delivers a clinical experience that helps men and woman live their best life, whether it’s through simple cosmetic procedures, pain-reducing
practices, or anti-aging therapies. Through its three locations, Sòlas prides itself on its dedicated service-focused, health-first
approach. Its wellness & rejuvenation clinics deliver with a focus on regenerative therapies, IV and injection services, cosmetic
enhancements amongst a myriad of additional health centric services.

 

 

 

 

 

  F-11  

 

 

International
Health Group (“IHG”)
– IHG provides highly trained nursing and medical assistants for hospitals and home health facilities
since 2006. IHG Medical Assistant programs include Certified Nursing Assistant (“CNA") and Home Health Aide (“HHA”)
training and the fast-track 22-Day CNA Certification Program at its state-approved testing facility.

 

Pacific
Stem Cells (“PSC”)
– PSC markets and sells traditional biologics and human cells, tissues, and cellular and tissue-based
products (HCT/Ps).

 

Watson
Rx Solutions (“Watson”)
– In June 2022, the Company acquired Watson, an Alabama-based pharmacy with more than 30 years
of experience in the retail medical and pharmaceutical industries. Watson helps manage disease states through education and prescription
management while offering generic as well as specialty medications. Watson maintains pharmacy licenses in all 50 States including Washington
D.C.

 

GlanHealth
(“GlanHealth”)
– Genefic Products launched GlanHealth in 2020 to distribute alcohol-free hand sanitizers, surface cleaners,
laundry aides, antimicrobial solutions, electrostatic sprayers, face masks, gloves, kits, and delivery equipment such as dispensers, stands,
and ease of use packaging for the end consumer. GlanHealth leverages an extensive supply chain of producers, resellers, distributors,
vendors, and formulators for the development, sale, and marketing of its products and services.

 

Dalrada Energy Services

 

Dalrada Energy Services (‘DES’)
employs next-generation technology that enhances clean energy efforts while reducing the world’s carbon footprint. Through innovative
products and commercial services, DES facilitates energy transition for universities, businesses, government buildings, and more.

 

Dalrada
Energy Services Inc. (“DES”)
– DES provides end-to-end comprehensive energy service solutions in a robust commercial capacity,
DES helps organizations meet environmental, social, and governance (“ESG”) goals and standards while mitigating negative environmental
impacts.

 

Bothof
Brothers Construction (“Bothof”)
– The Company acquired Bothof in November 2022. Bothof is a licensed general contractor
which provides a wide range of development, construction and design capabilities and expertise throughout the United States. Through Bothof’s
extensive experience in construction and contracting, the DES division is able to provide a myriad of additional services to its private
and public works customers.

 

Dalrada Precision Manufacturing

 

Dalrada Precision Manufacturing creates
total manufacturing solutions that start with the design and development of high-quality machine parts and components, and end with an
efficient global supply chain. This specialized business division can meet today’s high demands and solves industry challenges.
Dalrada Precision Manufacturing is confident that it redefines the critical quality of the world’s top components and responds with
in-house research, design, engineering, and distribution through a highly reliable global supply chain and improved time-to-market capabilities.

 

Dalrada
Precision Parts (“Precision”)
– Precision extends the client its engineering and operations team by helping devise unique
manufacturing solutions tailored to their products. Dalrada Precision can enter at any stage of the product lifecycle from concept and
design to mass production and logistics.

 

 

 

 

 

  F-12  

 

 

Likido
Ltd. (“Likido”)
– Likido is an international engineering company developing advanced solutions for the harvesting and recycling
of energy. Using its novel, heat pump systems (patent pending), Likido is working to revolutionize the renewable energy sector with the
provision of innovative modular process technologies to maximize the capture and reuse of thermal energy for integrated heating and cooling
applications. With uses across industrial, commercial and residential sectors, Likido provides cost savings and the minimized carbon emissions
across global supply chains. Likido’s technologies enable the effective recovery and recycling of process energy, mitigating against climate
change and expected enhancement of quality of life through the provision of low-carbon heating and cooling systems.   

 

Ignite
I.T. (“Ignite”)
– Ignite is a manufacturer and seller of eco-friendly deep cleaners, parts washers and degreasers that
are specially formulated to lift hydrocarbon-based dirt and grease from virtually all surfaces with minimal effort. Ignite products are
non-flammable, non-corrosive, non-toxic, butyl-free, water-based, and leave a light citrus scent. Ignite is developed for all surfaces
suitable for water and meet or exceed the most stringent industry-testing specifications. Ignites products are effective and available
solutions to the increased demand for protecting employees from hazardous chemicals currently used and highlighted in recent federal and
state regulations.

 

Deposition
Technologies (“DepTec”)
– Dalrada Precision Manufacturing acquired DepTec in April 2022. DepTec designs, develops, manufactures,
and services chemical vapor and physical vapor deposition systems for the microchip and semiconductor industries.

 

DepTec
has built a multitude of precision OEM parts for PVD (Physical vapor deposition) and refurbished systems which allow clients the option
of purchasing the same model of system they’ve been using for decades – but with upgrades and improved efficiencies. DepTec
also has its own PVD and CVD (Chemical Vapor Deposition) systems, EVOS-PVD and EVOS -CVD, which deposits metals and non-metals for microchips
used in almost every standard and specialized microdevices made today and in the future. These systems can produce a superior film layer
utilized in rugged high-stress environment designs and expect to meet the increased US market demand driven by the CHIPS and Science Act
of 2022.

 

Dalrada
Technology Limited (“DTL”)-
Dalrada Precision Manufacturing Inc. entered into an Ownership Purchase Agreement to purchase
all of the membership interests in Dalrada Technology Limited on March 1, 2023. DTL is a holding company for all European based Dalrada
Precision entities.

 

Dalrada
Technology Spain L.T. (“DTS”)-
DTS was established as a Spanish subsidiary of DTL for the expansion of the manufacturing
and sale of the Company’s heat pump technology throughout Europe.

 

Dalrada Technologies

 

Dalrada Technologies has worked with
some of the world’s most recognizable companies, providing digital engineering for cutting-edge software systems and offering a
host of robust digital services. This business division connects the world with integrated technology and innovative solutions, delivering
advanced capabilities and error-free results. Dalrada Technologies creates digital products with expert computer information technology
and software engineering services for a variety of technical industries and clients in both B2B and B2C environments.

 

Prakat (“Prakat”)– Prakat is
an ISO 9001-certified company that provides end-to-end technology services across various industries, improving the value chain. The Company
specializes in test engineering, accessibility engineering, product engineering, application modernization, billing and revenue management,
CRM, and block chain. Prakat provides global customers with software and technology solutions specializing in Test Engineering, Accessibility
Engineering, Product Engineering and Application Modernization.

 

Dalrada Corporate

 

Dalrada Corporate covers activities
which support the entire suite of Dalrada subsidiaries. Dalrada Corporate includes the areas of administration, finance, human resources,
legal advice, information technology, and marketing. It also contains executive management and shareholder-related services.

 

 

 

 

  F-13  

 

 

Going Concern

 

These consolidated financial statements
have been prepared on a going concern basis, which implies that the Company will continue to realize its assets and discharge its liabilities
in the normal course of business. As of June 30, 2023, and 2022, the Company had a working capital deficit of $202,420 and $ $9,357,651,
respectively. The Company incurred negative cash flows from operations for the years ended June 30, 2023, and 2022, and raises substantial
doubt about the Company’s ability to continue as a going concern. The continuation of the Company as a going concern is dependent
upon the successful financing through equity and/or debt investors and growing the subsidiaries anticipated to be profitable while reducing
investments in areas that are not expected to have long-term benefits. The Company expects to fund any short-term operational deficits
primarily through collection of outstanding accounts receivable from medical insurance providers, Medicare, pharmaceutical sales, the
sale of Likido units as well as loans from related parties.

  

2. Summary of Significant Accounting Policies

 

  (a) Basis of Presentation

 

These consolidated financial statements
of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America (“US
GAAP”) and are expressed in U.S. dollars. The Company’s fiscal year end is June 30.

 

  (b) Principles of Consolidation

 

The consolidated financial statements
include the accounts of the Company and its subsidiaries, as well as the accounts of any entities over which the Company has a controlling
financial interest in accordance with Accounting Standards Codification (“ASC”) 810 Consolidation. All transactions and balances
between these entities have been eliminated upon consolidation.

 

The consolidated financial statements
include the accounts of Dalrada Financial Corp., Genefic Products Inc., Solas Corp., Empower Genomics, Inc., International Health Group,
Inc., Pala Diagnostics, LLC, Pacific Stem Cells, LLC, Watson Rx Solutions, Inc., Shark Innovative Technologies Corp., Dalrada Precision
Corp., Dalrada Energy Services, Inc., Likido Corp., Ignite I.T., Bothof Brothers Construction Inc., Prakat Solutions, Inc., Prakat Solutions
Private Limited, Likido Ltd., Deposition Technologies Ltd. and Dalrada Technology Ltd., controlled by the Company through its direct or
indirect ownership of a majority voting interest. Additionally, the consolidated financial statements include the accounts of variable
interest entities (“VIEs”) in which the Company has a variable interest and for which the Company is the “primary beneficiary”
as it has both: (1) the power to direct the activities of the VIE that most significantly impact the VIE’s economic performance
and (2) the obligation to absorb losses of the VIE that potentially could be significant to the VIE or the right to receive benefits from
the VIE that potentially could be significant to the VIE. All significant intercompany accounts and transactions are eliminated in consolidation.

 

Income attributable to the minority
interest in the Company’s majority owned and controlled consolidated subsidiaries is recorded as net income attributable to noncontrolling
interests in the Consolidated Statements of Operations and Comprehensive Loss and the noncontrolling interest is reflected as a separate
component of the statement of stockholders’ equity, consolidated balance sheet, and statement of cash flows.

  

  (c) Use of Estimates

 

The preparation of these consolidated
financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts
of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and
the reported amounts of revenues and expenses during the reporting period. The Company regularly evaluates estimates and assumptions related
to the revenue, valuation of inventory, valuation of acquired assets and liabilities, variables used in the computation of share-based
compensation, litigation, and evaluation of goodwill and intangible assets for impairment.

 

 

 

 

 

  F-14  

 

 

The Company bases its estimates and
assumptions on current facts, historical experience, and various other factors that it believes to be reasonable under the circumstances,
the results of which form the basis for making judgments about the carrying values of assets and liabilities and the accrual of costs
and expenses that are not readily apparent from other sources. The actual results experienced by the Company may differ materially and
adversely from the Company’s estimates. To the extent there are material differences between the estimates and the actual results,
future results of operations will be affected.

 

  (d) Cash and Cash Equivalents

 

Cash and cash equivalents include cash
deposits in financial institutions, and the Company considers all highly liquid instruments with a maturity of three months or less at
the time of issuance to be cash equivalents.

 

  (e) Concentrations of Credit Risk

 

Financial instruments that potentially
subject the Company to concentrations of credit risk consist principally of cash, accounts receivable, and cash equivalents. The Company
generally maintains balances in various operating accounts at financial institutions that management believes to be of high credit quality,
in amounts that may exceed federally insured limits. The Company has not experienced any losses related to its cash and cash equivalents
and does not believe that it is subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships.

 

When estimating its allowance for credit
losses related to revenues from Covid Testing, the Company differentiates its receivables based on the following customer types: healthcare
insurers, government payers, and cash payers. Additionally, the Company applies assumptions and judgments for assessing collectability
and determining net revenues and accounts receivable from its customers. Management considers various historical collection factors for
assessing collectability and determining net revenues and accounts receivable from our customers which include the period that the receivables
have been outstanding, history of payment amounts, status of collections due, and applicable statutes of limitations.

 

During the year ended June 30, 2023
and 2022, healthcare insurers and government payers accounted for over 42% and 61% of total revenues, respectively. Also, healthcare insurers
and government payers amounted to total revenues of $12,546,849 and $11,824,717 for the years ended June 30, 2023 and 2022, respectively.
The accounts receivable related to both healthcare insurers and government payers is $1,499,415 and $4,129,953 as of June 30, 2023 and
2022, respectively.

 

During the year ended June 30, 2023, DES’s Averett University
project accounted for $3,741,494, or 12% of total revenues.

 

As of June 30, 2023 and 2022, $829,239
and $880,500 is owed by customers from the sale of Likido units, respectively.

 

  (f) Fair Value Measurements

 

Pursuant to ASC 820, Fair Value
Measurements and Disclosures
, an entity is required to maximize the use of observable inputs and minimize the use of unobservable
inputs when measuring fair value. ASC 820 establishes a fair value hierarchy based on the level of independent, objective evidence surrounding
the inputs used to measure fair value. A financial instrument’s categorization within the fair value hierarchy is based upon the
lowest level of input that is significant to the fair value measurement. ASC 820 prioritizes the inputs into three levels that may be
used to measure fair value:

 

Level 1 – applies to assets or liabilities
for which there are quoted prices in active markets for identical assets or liabilities.

 

Level 2 – applies to assets or liabilities
for which there are inputs other than quoted prices that are observable for the asset or liability such as quoted prices for similar assets
or liabilities in active markets; quoted prices for identical assets or liabilities in markets with insufficient volume or infrequent
transactions (less active markets); or model-derived valuations in which significant inputs are observable or can be derived principally
from, or corroborated by, observable market data.

 

Level 3 – applies to assets or liabilities
for which there are unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of the
assets or liabilities.

 

 

 

  F-15  

 

 

The Company’s financial instruments
consist principally of cash, accounts receivable, accounts payable and accrued liabilities, notes payable, and amounts due to related
parties. Pursuant to ASC 820, the fair value of cash is determined based on “Level 1” inputs, which consist of quoted prices
in active markets for identical assets. The recorded values of all other financial instruments approximate their current fair values because
of their nature and respective maturity dates or durations.

 

The fair value of the contingent consideration
obligations was based on a probability weighted approach derived from the estimates of earn-out criteria and the probability assessment
with respect to the likelihood of achieving those criteria. The measurement was based on significant inputs that were not observable
in the market, therefore, the Company classified this liability as Level 3 in the following tables: 

                       
    Fair Value Measurements as of June
30, 2023 Using:
 
    Level 1     Level 2     Level 3     Total  
Liabilities:                        
Contingent consideration               $ 4,285,389     $ 4,285,389  
    $     $     $ 4,285,389     $ 4,285,389  

 

    Fair Value Measurements as of June
30, 2022 Using:
 
    Level 1     Level 2     Level 3     Total  
Liabilities:                        
Contingent consideration               $ 4,870,800     $ 4,870,800  
    $     $     $ 4,870,800     $ 4,870,800  

 

 

The Company records a contingent consideration
liability relating to stock price guarantees included in its acquisition and consulting agreements. The estimated fair value of the contingent
consideration is recorded using a significant observable measure and is therefore classified as a Level 3 financial instrument.

 

The fair value of the contingent consideration
liability related to the Company’s business combinations is valued based on a forward contract and the guaranteed equity value at
settlement as defined in the acquisition agreement (see “Note 4. Business Combinations and Asset Acquisition). The fair value of
the contingent consideration is then calculated based on the guaranteed equity value at settlement as defined in the acquisition agreement.
(See “Note 14. Commitments and Contingencies”).

 

 

 

 

 

  F-16  

 

 

Changes in contingent consideration
liability during the year ended June 30, 2023, and 2022, are as follows: 

       
    Contingent  
    Consideration  
    Liability  
Balance as of June 30, 2022   $ 4,870,800  
Change in fair value     (585,411 )
Balance as of June 30, 2023   $ 4,285,389  

 

    Contingent  
    Consideration  
    Liability  
Balance as of June 30, 2021   $  
Initial recognition in connection with acquisition of Deptec     5,053,000  
Change in fair value     (182,200 )
Balance as of June 30, 2022   $ 4,870,800  

 

 

  (g) Convertible Instruments

 

The Company evaluates and accounts
for conversion options embedded in convertible instruments in accordance with ASC Topic 815, Derivatives and Hedging Activities (“ASC
815”).

 

Applicable U.S. GAAP requires companies
to bifurcate conversion options from their host instruments and account for them as free-standing derivative financial instruments according
to certain criteria. The criteria includes circumstances in which (a) the economic characteristics and risks of the embedded derivative
instrument are not clearly and closely related to the economic characteristics and risks of the host contract, (b) the hybrid instrument
that embodies both the embedded derivative instrument and the host contract is not re-measured at fair value under otherwise applicable
generally accepted accounting principles with changes in fair value reported in earnings as they occur and (c) a separate instrument with
the same terms as the embedded derivative instrument would be considered a derivative instrument.

 

The Company accounts for convertible
instruments (when the Company has determined that the embedded conversion options should not be bifurcated from their host instruments)
as follows. The Company records, when necessary, deemed dividends for the intrinsic value of conversion options embedded in shares based
upon the differences between the fair value of the underlying common stock at the commitment date of the transaction and the effective
conversion price embedded in the shares. 

 

 

 

 

 

 

  F-17  

 

 

  (h) Accounts Receivable

 

Accounts receivables are derived from
products and services delivered to customers and are stated at their net realizable value. Each month, the Company reviews its receivables
on a customer-by-customer basis and evaluates whether an allowance for doubtful accounts is necessary based on any known or perceived
collection issues.  Any balances that are eventually deemed uncollectible are written off against the allowance after all means of
collection have been exhausted and the potential for recovery is considered remote. As of June 30, 2023, and 2022, the Company had an
allowance of doubtful accounts of $2,430,615 and $119,791, respectively.

 

Pala and Empower have a standardized
approach to estimate the amount of consideration that we expect to be entitled to for its COVID-19 testing revenue, including the impact
of contractual allowances (including payer denials), and patient price concessions. The Company principally estimates the allowance for
credit losses by pool based on historical collection experience, the current credit worthiness of the customers, current economic conditions,
expectations of future economic conditions and the period of time that the receivables have been outstanding. Adjustments to our estimated
contractual allowances and implicit patient price concessions are recorded in the current period as changes in estimates.

 

  (i) Inventory

 

Inventory is recorded at the lower
of cost or net realizable value on a first-in first-out (“FIFO”) basis. As of June 30, 2023 and 2022, inventory is comprised
of raw materials purchased from suppliers, work-in-progress, and finished goods produced or purchased for resale. The Company establishes
inventory reserves for estimated obsolete or unsaleable inventory equal to the difference between the cost of inventory and the estimated
realizable value based upon assumptions about future market conditions.

 

  (j) Property and Equipment

 

Property and equipment are stated
at cost less accumulated depreciation and amortization. Depreciation and amortization expense is recognized using the straight-line method
over the estimated useful life of each asset, as follows: 

   
    Estimated Useful Life
Computer and office equipment   3 – 5 years
Machinery and equipment   5 years
Leasehold improvements   Shorter of lease term or useful life

 

Estimated useful lives are periodically
assessed to determine if changes are appropriate. Maintenance and repairs are charged to expense as incurred. When assets are retired
or otherwise disposed of, the cost of these assets and related accumulated depreciation or amortization are eliminated from the Consolidated
Balance Sheet and any resulting gains or losses are included in the Consolidated Statement of Operations in the period of disposal.

 

 

 

 

 

  F-18  

 

 

  (k) Business Combinations and Asset Acquisitions

 

The Company accounts for acquisitions
in which it obtains control of one or more businesses as a business combination. The purchase price of the acquired businesses is allocated
to the tangible and intangible assets acquired and liabilities assumed based on their estimated fair values at the acquisition date. The
excess of the purchase price over those fair values is recognized as goodwill. During the measurement period, which may be up to one year
from the acquisition date, the Company may record adjustments, in the period in which they are determined, to the assets acquired and
liabilities assumed with the corresponding offset to goodwill. If the assets acquired are not a business, the Company accounts for the
transaction or other event as an asset acquisition. Under both methods, the Company recognizes the identifiable assets acquired, the liabilities
assumed, and any noncontrolling interest in the acquired entity. In addition, for transactions that are business combinations, the Company
evaluates the existence of goodwill or a gain from a bargain purchase.

 

  (l) Contingent Consideration

 

A Company acquisition includes contingent
consideration as part of the purchase price. The fair value of the contingent consideration is estimated as of the acquisition date based
on the present value of the contingent payments to be made using a weighted probability of possible payments. The unobservable inputs
used in the determination of the fair value of the contingent consideration include managements assumptions about the likelihood of payment
based on the established benchmarks and discount rates based on internal rate of return analysis. The fair value measurement includes
inputs that are Level 3 measurement as discussed in Note 4 to our consolidated financial statements included in this annual report on
Form 10-K. Should actual results increase or decrease as compared to the assumption used in our analysis, the fair value of the contingent
consideration obligations will increase or decrease, up to the contracted limit, as applicable. Changes in the fair value of the contingent
earn-out consideration could cause a material impact and volatility in our operating results. The contingent consideration decreased by
$585,411 to a balance of $4,285,389 during the year ended June 30, 2023.

  

  (m) Impairment of Long-Lived Assets

 

The
Company reviews its long-lived assets (property and equipment and amortizable intangible assets) for impairment whenever events or circumstances
indicate that the carrying amount of an asset may not be recoverable. If the sum of the expected cash flows, undiscounted, is less than
the carrying amount of the asset, an impairment loss is recognized as the amount by which the carrying amount of the asset exceeds its
fair value.

 

Goodwill is tested annually at June
30 for impairment and upon the occurrence of certain events or substantive changes in circumstances.

 

The annual goodwill impairment test
allows for the option to first assess qualitative factors to determine whether it is more likely than not that the fair value of a reporting
unit is less than its carrying amount. An entity may choose to perform the qualitative assessment on none, some or all of its reporting
units or an entity may bypass the qualitative assessment for any reporting unit and proceed directly to step one of the quantitative impairment
tests. If it is determined, on the basis of qualitative factors, that the fair value of a reporting unit is, more likely than not, less
than its carrying value, the quantitative impairment test is required. The quantitative impairment test calculates any goodwill impairment
as the difference between the carrying amount of a reporting unit and its fair value, but not to exceed the carrying amount of goodwill.
As of June 30, 2023 and 2022, there were quantitative factors that indicated goodwill was impaired in the amounts of $433,556 and $218,308,
respectively.

 

An intangible asset is an identifiable
non-monetary asset without physical substance. Such an asset is identifiable when it is separable, or when it arises from contractual
or other legal rights. Separable assets can be sold, transferred, licensed, etc. Examples of intangible assets include computer software,
licenses, trademarks, patents, films, and copyrights. The Company’s intangible assets are finite lived assets and are amortized
on a straight-line basis over the estimated useful lives of the assets.

 

 

 

 

  F-19  

 

 

  (n) Revenue Recognition

 

The Company determines revenue recognition
in accordance with ASU 2014-09, Revenue from Contracts with Customers, and its related amendments (collectively known as “ASC
606”) through the following steps:

 

  Identification of a contract with a customer;

 

  Identification of the performance obligations in the contract;

 

  Determination of the transaction price;

 

  Allocation of the transaction price to the performance obligations in the contract; and

 

  Recognition of revenue when or as the performance obligations are satisfied.

 

Revenue is recognized when control
of the promised goods or services is transferred to customers, in an amount that reflects the consideration the Company expects to be
entitled to in exchange for those goods or services. As a practical expedient, the Company does not adjust the transaction price for the
effects of a significant financing component if, at contract inception, the period between customer payment and the transfer of goods
or services is expected to be one year or less.

 

The Company’s revenue is derived
from the sales of its products, which represents net sales recorded in the Company’s Consolidated Statements of Operations. Product
sales are recognized when performance obligations under the terms of the contract with the customer are satisfied. Typically, this would
occur upon transfer of control, including passage of title to the customer and transfer of risk of loss related to those goods. The Company
measures revenue as the amount of consideration to which it expects to be entitled in exchange for transferring goods (transaction price).
The Company records reductions to revenue for estimated customer returns, allowances, markdowns, and discounts. The Company bases its
estimates on historical rates of customer returns and allowances as well as the specific identification of outstanding returns, markdowns
and allowances that have not yet been received by the Company. The actual amount of customer returns and allowances is inherently uncertain
and may differ from the Company’s estimates. If the Company determines that actual or expected returns or allowances are significantly
higher or lower than the reserves it established, it will record a reduction or increase, as appropriate, to net sales in the period in
which it makes such a determination. Reserves for returns and markdowns are included within accrued expenses and other liabilities in
the Company’s Consolidated Balance Sheets. Allowance and discounts are recorded in accounts receivable, net and the value of inventory
associated with reserves for sales returns are included within prepaid expenses and other current assets in the Consolidated Balance Sheets.

  

The Company estimates warranty claims
reserves based on historical results and research and determined that a warranty reserve was not necessary as of June 30, 2023, or 2022.

 

 

 

 

 

  F-20  

 

 

Net revenues from COVID-19 testing
accounted for over 34% and 61% of the Company’s total net revenues for the years ended June 30, 2023 and 2022, respectively, and
primarily comprised of a high volume of relatively low-dollar transactions. Pala and Empower, which provides clinical testing services
and other services, satisfies its performance obligations and recognizes revenues primarily upon completion of the testing process (when
results are reported) or when services have been rendered. Pala and Empower do not invoice the patients themselves for testing but relies
on healthcare insurers and government payers for reimbursement for COVID-19 testing. Pala has a standardized approach to estimate the
amount of consideration that we expect to be entitled to, including the impact of contractual allowances (including payer denials), and
patient price concessions. We regularly assess the state of our billing operations in order to identify issues which may impact the collectability
of receivables or revenue estimates. We believe that the collectability of our receivables is directly linked to the quality of our billing
processes, most notably those related to obtaining the correct information in order to bill effectively for the services we provide. As
such, we strive to implement “best practices” and work with our third-party billing company to reduce the number of requisitions
that we receive from healthcare providers with missing or incorrect billing information. We believe that our collection and revenue estimation
processes, along with our close monitoring of our billing operations, help to reduce the risk associated with material adjustments to
reserve estimates. However, changes to our estimate of the impact of contractual allowances (including payer denials) and patient price
concessions could have a material impact on our results of operations and financial condition in the period that the estimates are adjusted.
Adjustments to our estimated contractual allowances and implicit patient price concessions are recorded in the current period as changes
in estimates. Although we have limited track record, further adjustments to the allowances, based on actual receipts, may be recorded
upon settlement.

 

DES recognizes revenue on energy savings
contracts where it provides design, engineering and equipment upgrades to obtain energy savings through Environmental, Social, and Governance
(“ESG”) targets. DES recognizes revenue through two performance obligations: 1) the Energy Savings Report (point in time);
and 2) functional IP license (point in time with a significant financing component and royalty and variable consideration constraint).
Up to and upon completion of an energy savings project, DES calculates the monthly energy savings based on prior and current energy consumption
totals. Upon completion of a project, the customer pays monthly fixed payments which represents a financing component. DES recognized
monthly interest income and “royalty” revenue when the constraint from the energy savings percentage is known. DES records
revenue as it provides additional management, consulting, and other services as they are incurred.

 

DES records a sales-type where the
Company is the lessor. The Company records its investment in the plant and equipment, used to upgrade a customer’s real property,
leased to franchisees on a net basis, which is comprised of the present value of fixed lease payments not yet received over the course
of the energy savings agreements. The current and long-term portions of our net investment in sales-type leases are included in “Accounts
Receivable, net – related parties” and “Long-term receivables – related parties” respectively in the Consolidated
Balance Sheets. Unearned income is recognized as interest income over the lease term. Sales-type leases result in the recognition of gain
or loss at the commencement of the lease, which is recorded to “Revenues – related party” in the Consolidated Statements
of Operations and Comprehensive Loss.

 

DepTec and Bothof recognize revenues
using a cost-based input method, by which we use actual costs incurred relative to the total estimated contract costs to determine, as
a percentage, progress toward contract completion. Provisions for estimated losses on uncompleted contracts are made in the period in
which such losses are determined.

 

The Company also earns service revenue
from its other subsidiaries, including information technology and consulting services via Prakat, educational programs, and courses via
IHG, management services for Solas, and custom parts manufacturing for Dalrada Precision Parts. For Prakat, Solas and Dalrada Precision
Parts, revenues are recognized when performance obligations have been satisfied and the services are complete. This is generally at a
point of time upon written completion and client acceptance of the project or product, which represents transfer of control to the customer.
For IHG, revenues are recognized over the course of a semester while services are performed.

 

 

 

 

 

  F-21  

 

 

Disaggregation of Revenue

 

The following table presents the Company’s
revenue disaggregated by revenue source: